

*Author manuscript published in: BBA - General Subjects*

# Perturbation of genome integrity to fight pathogenic microorganisms

**Kinga Nyíri<sup>1,2\*</sup>** and **Beáta G. Vértessy<sup>1,2\*</sup>**

<sup>1</sup> Dept. Biotechnology, Budapest University of Technology and Economics, 4 Szent Gellért tér, Budapest, Hungary, 1111

<sup>2</sup> Institute of Enzymology, RCNS, Hungarian Academy of Sciences, 2 Magyar tudósok körútja, Budapest, Hungary, 1117

\*To whom correspondence should be addressed. Beáta G. Vértessy. Tel:+36 1 463 3854; Fax: +36 1 463 3855; Email: [vertessy@mail.bme.hu](mailto:vertessy@mail.bme.hu).

Correspondence may also be addressed to Kinga Nyíri. Tel:+36 1 463 1401; Fax: +36 1 463 3855; Email: [nyiri.kinga@ttk.mta.hu](mailto:nyiri.kinga@ttk.mta.hu).

## Keywords

Thymidylate biosynthesis, DNA repair, dUTPase, thymidylate synthase, ThyX, Mycobacteria, Plasmodium, drug resistance

## 17   **Abstract**

18   **Background:** Resistance against antibiotics is unfortunately still a major biomedical  
19 challenge for a wide range of pathogens responsible for potentially fatal diseases.

20   **Scope of Review:** In this study, we aim at providing a critical assessment of the recent  
21 advances in design and use of drugs targeting genome integrity by perturbation of thymidylate  
22 biosynthesis.

23   **Major Conclusion:** We find that research efforts from several independent laboratories  
24 resulted in chemically highly distinct classes of inhibitors of key enzymes within the routes of  
25 thymidylate biosynthesis. The present article covers numerous studies describing perturbation  
26 of this metabolic pathway in some of the most challenging pathogens like *Mycobacterium*  
27 *tuberculosis*, *Plasmodium falciparum*, and *Staphylococcus aureus*.

28   **General Significance:** Our comparative analysis allows a thorough summary of the current  
29 approaches to target thymidylate biosynthesis enzymes and also include an outlook suggesting  
30 novel ways of inhibitory strategies.

## Highlights

- critical assessment of approaches against enzymes in thymidylate biosynthesis
- detailed assessment of perturbation strategies to inhibit various families of dUTPases, thymidylate synthases and dihydrofolate reductases
- focus on the biomedically most challenging pathogens
- identification of novel strategies by e.g. proteinaceous inhibition

## Abbreviations

CH<sub>2</sub>THF: 5,10-methylene tetrahydrofolate, DCD: dCTP deaminase, DCD-DUT:bifunctional dCTP deaminase – dUTPase, DUT: dUTPase, DHF: dihydrofolate, DHFR: dihydrofolate reductase, DHFR-TS bifunctional dihydrofolate reductase – thymidylate synthase, FAD: flavin adenine dinucleotide, SHMT: serine hydroxymethyltransferase, THF: tetrahydrofolate, TK: thymidine kinase, TS, ThyX: classical and flavin-dependent thymidylate synthase, TMPK: dTMP kinase, Ugi: uracil-DNA glycosylase inhibitor, UNG: uracil-DNA N-glycosylase. Abbreviations of organisms are listed in Table 1.

## Background

Despite huge efforts in antimicrobial drug design, numerous microbes still present excessive biomedical challenge all around the world, in less developed and highly developed countries alike. Major reasons for this unfortunate situation include several factors. Among these, high mutation rate in many pathogenic organisms that may be an inherent characteristic of bacterial species (e.g. presence of error-prone polymerases in *Mycobacterium tuberculosis* may lead to resistant strains [1]). Also, the over-excessive use of antibiotics drives the development of resistance. In this respect it is important to note that overuse of antibiotics in animal agriculture is a major hazard especially since these are frequently the very same chemical compounds that are used in human medicine. Antibiotics in the livestock and poultry feed presents a low-level exposure over long periods of time that strongly contribute to the appearance of resistant microbial strains. Wide availability of antibiotics is also a concern. Although in some countries, there is an increasingly cautious attitude towards prescribing antibiotics in minor illnesses, still, in many situations, prescriptions are easy to obtain for larger amounts of antibiotics, sometimes even as over-the-counter-drugs, as well. In addition to all these, patients carrying pathogenic microbes may easily spread the infection among different populations as traveling is largely facilitated *via* flights and other means of transport.

The most efficient way to overcome the problems of microbial resistance against drugs is to focus on new pathways, to discover novel molecular targets such that the strains that became resistant against the “old” drugs could not rely on the already developed resistance mechanism. Despite the general agreement in these questions, the number of novel antibiotics with a new molecular mechanism of action developed over the last decades is very low. This is perhaps at least partially, but maybe mostly, due to the fact that the development of antibiotics is not among the most profitable actions for a drug company. Development of new drugs is a very complex and costly project, with inherent problems relating to unexpected side-effects when a pathway or protein is targeted that has not been previously among those affected by drugs in clinical use. Approval of novel drugs is also a lengthy and expensive process. These factors are deterrent for large pharmaceutical companies and contribute to the present suboptimal situation.

No matter how few truly novel antimicrobial drugs have been introduced in the clinical use during the last years, the basic research background is much flourishing. Even a quick and superficial view on the number and variety of studies published in this context strongly argues

for the high momentum in the academic research on these fields. The present study attempts to cover most of the recent developments, focusing on investigations related to inhibition of enzymes involved in thymidylate biosynthesis as a novel target in multiple pathogenic microorganisms (Table 1).

## **Genome integrity and thymidylate biosynthesis – why it is a promising field for novel drug candidates?**

For an effective drug candidate, the target protein has to be essential for the given organism. Microbe-specific enzymes are traditionally considered to be the best targets, however, in many instances, enzymes where homologues are also present in the host organism still may be good targets for design of antimicrobial diseases. Hence, the wealth of information gained on more complex eukaryotic systems, e.g. in cancer research may also be used in the research against infectious microbes. The common denominator in these issues may be found when we focus on the joint characteristics of infectious microbes and cancer cells – namely, during acute phases of the disease, these cells are all multiplying very fastly and drugs interfere with this increased division cycle. In the present study, we focus on thymidylate biosynthesis that is part of the preventive DNA repair pathways and responsible for maintaining genome integrity (Figure 1). Perturbation of this metabolic pathway was proven to be an important pharmaceutical strategy for both cancer and microbial cells.

Thymidylate biosynthesis shows several characteristics different from the biosynthesis of other nucleic acid building blocks (Figure 1). Most importantly, the *de novo* biosynthesis of the thymine base is realized at the monophosphate nucleotide level from dUMP, provided mostly by the dUTPase enzyme, through the catalytic action of thymidylate synthases (TS or ThyX). The methyl group transfer to the 5'-position in the pyrimidine ring requires complex biochemical catalysis. Thymine containing nucleotides can also be regained by salvage pathways through thymidine kinase. The rather limited and constrained routes in thymidylate biosynthesis, together with its essentiality for DNA biosynthesis designates the enzymes within these pathways as key targets for development of antimicrobial drugs, while the human homologues of these enzymes are also very important entities in anticancer chemotherapy. Nevertheless both thymidylate synthase and dihydrofolate reductase enzymes are heavily studied primary enzymatic targets of antibacterial/antiparasite therapy [2,3]. However, there are other important drug targets amongst the folate pathway enzymes, for example

112 dihydropteroate synthase. Due to the indirect connection of these enzymes to dTTP  
113 biogenesis, detailed presentation of these are out of the scope of this review.


114 Below, we will summarize in a comparative manner the current advances in application of  
115 enzymes involved in thymidylate biosynthesis as drug targets in several pathogens that still  
116 present major biomedical challenge (Table 1).

117

118 **Table 1 List of organisms and their human relevance included in this study**

Organism (Abbreviation)	Human relevance	Section
<i>Bacillus anthracis</i> (Ba)	etiologic agent of anthrax	DHFR, TMPK
<i>Campylobacter jejuni</i> (Cj)	gastric pathogen	DUT
<i>Candida glabrata</i> (Cg) <i>Candida albicans</i> (Ca)	systemic infection agent	DHFR
<i>Cryptococcus neoformans</i>	causative of fungal meningitis and encephalitis	TS
<i>Cryptosporidium hominis</i> , (Ch) <i>Cryptosporidium parvum</i> (Cp)	gastric pathogen	DHFR-TS, TK
<i>Enterococcus faecalis</i> (Ef)	causative of urinary tract infections and endocarditis	TS, DHFR
<i>Helicobacter pylori</i> (Hp)	gastric pathogen	ThyX
<i>Klebsiella pneumoniae</i> (Kp)	causative of urinary and respiratory tract infections	DHFR
<i>Lactobacillus casei</i> (Lc)	LcTS is a model protein of classical TSs	TS
<i>Leishmania donovani</i> (Ld)	causative of visceral leishmaniasis (black fever)	DHFR-TS
<i>Leishmania major</i> (Lm)	causative of cutaneous leishmaniasis	DUT, DHFR-TS, TK
<i>Mycobacterium tuberculosis</i> (Mt)	causative of tuberculosis	DUT, DHFR ThyX,
<i>Paramecium bursaria chlorella virus-1</i> (PBCV)	PBCV-ThyX is a model protein of ThyX	ThyX
<i>Plasmodium falciparum</i> (Pf) <i>Plasmodium vivax</i> (Pv) <i>Plasmodium ovale</i> (Po)	causatives of malaria	DUT, DHFR-TS
<i>Pneumocystis carinii</i> (Pc) <i>Pneumocystis jirovecii</i> (Pj)	causatives of <i>Pneumocystis</i> pneumonia	TS, DHFR
<i>Pseudomonas aeruginosa</i> (Pa)	causative of urinary tract and blood infections	TMPK
<i>Staphylococcus aureus</i> (Sa)	causative of skin and respiratory infections	TS, DHFR, TMPK
<i>Staphylococcus epidermidis</i> (Se)	causative agent of endocarditis, infects medical catheters and prostheses	TS
<i>Streptococcus mutans</i> (Sm)	major aetiological agent of dental caries	DHFR
<i>Toxoplasma gondii</i> (Tg)	causative of toxoplasmosis	DHFR-TS
<i>Trypanosoma brucei</i> (Tb)	causative of African sleeping sickness (African trypanosomiasis)	DUT, DHFR-TS, TK
<i>Trypanosoma cruzi</i> (Tc)	causative of Chagas disease (American trypanosomiasis)	DUT, DHFR-TS, SHMT

119



132



## 1. dUTPase inhibition

The role of the dUTPase enzyme, catalyzing the hydrolysis of dUTP into dUMP and inorganic pyrophosphate is dual: on the one hand, it provides the dUMP precursor for dTTP *de novo* biosynthesis, while on the other hand, the enzyme keeps the level of cellular dUTP at a low value such that to prevent incorporation of uracil moieties into DNA [4]. This preventive action has great significance due to the suboptimal specificity of most DNA polymerases that will incorporate either dUMP or dTMP against the dAMP, simply depending on the cellular availability of dUTP versus dTTP. There are two major families of dUTPases: the trimeric dUTPases are especially widespread, while the dimeric dUTPases are found in some parasites and some phages (Figure 2) [4,5]. The overall structures as well as active site close-ups for these two dUTPase families are shown in Figure 2. In addition to the dUTP substrate, these active sites provide a specific environment for the catalytic water molecule that initiates nucleophilic attack at the  $\alpha$ - or  $\beta$ -phosphorus atom (for trimeric, and dimeric dUTPases, respectively). Divalent metal ions also play an important role in the catalysis: in trimeric dUTPases, Mg(II) ion is present coordinating to the triphosphate chain, whereas in dimeric dUTPases, two divalent metal ions are involved in the catalytic steps.


Considering that the human dUTPase also belongs to the trimeric family, the dimeric enzyme family (present in some parasites) perhaps provides a more straightforward dUTPase target, with potentially less side effects due to the large differences in the pathogen and host enzymes (cf Table 2). Such efforts singled out very effectively the dUTPases from *Leishmania*, *Trypanosoma* and *Campylobacter* species. Essentiality of dUTPases in these organisms was investigated and established in *Trypanosoma brucei* by RNAi [6]. In these cases, dissimilarities between the dUTP binding sites of the pathogen and the human enzymes presented a clear-cut starting point for development of drug candidates presumably showing less side effects [7–9]. Inhibitor design was performed by analyzing the high-resolution 3D crystal structures based on either small scale rational design or large scale *in silico* screening [10].

With regard to the trimeric family of dUTPases, two major pathogens were at the focus of relevant research efforts in targeting dUTPase (Table 2). Namely, *Mycobacterium tuberculosis* and *Plasmodium falciparum*, the causative agents of tuberculosis and malaria, respectively. In both of these organisms, the significance of the dUTPase enzyme in thymidylate biosynthesis is strongly enhanced due to the lack of salvage pathways [4,11]. The

3D structures of *M. tuberculosis* and *P. falciparum* dUTPases were published in 2004 and 2005, respectively [12,13]. These structures formulated the basis for further studies. A quick and reliable dUTPase activity assay developed for *M. tuberculosis* dUTPases facilitated further high-throughput searches for inhibitor molecules potentially targeting species-specific segments in *M. tuberculosis* dUTPases [14]. An integrated approach starting from the ZINC molecule database and using more than 2 million drug-like compounds in a virtual screening provided a short list of promising candidates [15,16]. Importantly, this study utilized an innovative novel concept that can be possibly termed as “allosteric drug design”. Namely, in order to avoid potential side effects, the protein surface that was targeted in this study constituted by an essential species-specific segment of the mycobacterial dUTPase [17], in the vicinity of the highly conserved active site. The best performing drug candidates were successfully tested in *in vitro* assays and animal models (guinea pig) as well [15]. This approach showed a model case for a highly potential integrated method in drug design starting from the already available drug compound library.

Similar high throughput searches were carried out in compound libraries of several thousands of candidate molecules for *Plasmodium falciparum* dUTPases [18]. The resulting considerations focused on the important observation that the uracil ring is of utmost importance in binding of ligands to the active site, whereas more variation is allowed at the 3' and 5' substituents [19]. Selectivity of the drugs against the pathogen and the human enzyme was also tested and the best performing drug candidates showed more than 200-fold selectivity [20]. This result is suggested to be further combined with transfer factors that may facilitate accumulation of the drugs within the parasite. Ongoing research in this field very recently focused on QSAR models facilitating design of novel compounds [21].

In spite of the vast number of studies and approaches there is still much to do in this field to arrive at a clinically tested drug candidate that may be the focus of further processes potentially resulting in approval of dUTPase inhibitors as antimicrobial drugs.



**Figure 2. Comparison of trimeric and dimeric dUTPases.** **A)** Cartoon representation of the trimeric *Mycobacterium tuberculosis* dUTPase (PDB ID:2PY4, [14]), chains colored by yellow, salmon and cyan. Substrate analogue dUPNPP shown as sticks with atomic coloring (carbon: black, oxygen: red, phosphorus: orange, nitrogen: blue) **B)** Cartoon representation of the dimeric *Leishmania major* dUTPase (PDB ID:2YAY, [7]), chains colored by yellow and cyan, substrate analogue dUPNPP shown as sticks with atomic coloring (carbon: black, oxygen: red, phosphorus: orange, nitrogen: blue). **C)** Active center of *MtDut* (PDB ID:2PY4, [14]), colored as in panel A, residues important for substrate binding and catalysis are shown as sticks with atomic coloring (carbon: colored by chain, oxygen: red, nitrogen: blue), catalytic magnesium and water as green and red spheres, respectively. Substrate analogue dUPNPP shown as sticks with atomic coloring as in Panel A. Dashed lines represent hydrogen-bonding interactions. **D)** Active center of *LmDut* (PDB ID:2YAY, [7]) colored as in Panel B, residues important for substrate binding and catalysis are shown as sticks with atomic coloring (carbon: colored by chain, oxygen: red, nitrogen: blue), catalytic calciums and water as green and red spheres respectively. Substrate analogue dUPNPP shown as sticks with atomic coloring as in Panel B. Dashed lines represent hydrogen-bonding interactions.

211 **Table 2.** Recent results on the inhibition of dUTPases

Organism	Year	Summary	Ref.
<i>Leishmania major</i>	1997	Identifying <i>LmDut</i> . Lysates of <i>E. coli</i> showed significant dUTPase activity increase after orthologous expression <i>LmDut</i> gene.	[22]
	2000	Verification of dimeric form of <i>LmDut</i> . dUDP and dUTP are both substrates of <i>LmDut</i> (dUDP is inhibitor of trimeric dUTPases).	[23]
	2001	Kinetic parameters of <i>LmDut</i> for dUTP hydrolysis are comparable to that of <i>hDut</i> . Dissimilarities in the binding of dUDP and dUMP as compared to the human enzyme suggest differences in the structure of the active sites.	[24]
	2011	Crystal structure of <i>LmDut</i> in complex with substrate analogues, product dUMP, and a substrate fragment (dU). Very tight ligand binding pocket modifications at the uracil or ribose rings might perturb binding of an inhibitor. The presence of a single phosphate or similarly charged group is important to induce ligand binding conformation of <i>LmDut</i> .	[7]
<i>Trypanosoma cruzi</i>	2004	Crystal structure of <i>TcDut</i> . Major differences between the substrate binding pocket of dimeric and trimeric dUTPases provides potential for selective inhibitor design. It was observed for the first time that ligand binding induces large conformational change in case of dimeric dUTPases.	[8]
	2006	Inhibitor design based on <i>in silico</i> docking. No <i>in vivo</i> and <i>in vitro</i> effects of the compounds. Protein flexibility has to be taken into account.	[10]
<i>Trypanosoma brucei</i>	2008	The dimeric <i>TbDut</i> is a nuclear enzyme and down-regulation of its activity by RNAi proved that <i>TbDut</i> is indispensable for efficient cell cycle progression and DNA replication in <i>T. brucei</i>	[6]
	2013	Conditional <i>Dut</i> knockout without adding thymidine caused impaired proliferation and lethality in <i>T. brucei</i> . Adding uracil, uridine or deoxyuridine could not rescue this phenotype. dUTPase has major role in the provision of pyrimidine nucleotides in kinetoplastids.	[25]
	2013	Crystallographic and NMR studies revealed that similarly to <i>CjDut</i> in case of <i>TbDut</i> nucleophilic attack also occurs on the $\beta$ -phosphate of the substrate. Unlike in the trimer enzymes in case <i>TbDut</i> one of the divalent metal ions plays direct role in catalysis.	[26]
<i>Campylobacter jejuni</i>	2004	The crystal structure of <i>CjDut</i> . $Mg^{2+}$ is important in enzymatic action. It was shown for the first time, that nucleophilic attack occurs on the $\beta$ -phosphate in contrast to the trimeric enzymes, where it happens at the $\alpha$ -phosphate. Ligand binding causes large conformational change so as in the case of <i>TcDut</i> [8].	[9]
	2009	Difference in inhibition constants as compared to the trimeric dUTPase enzymes permits the design of specific inhibitors of <i>CjDut</i> .	[27]
	2011	Crystal structure of <i>CjDut</i> with dUPNPP substrate analogue contains only two metal ions at the active site, while in the dUPNP complex three of those	[7]

		were indentified. Glu49 is flipped away from the active site in the presence of the triphosphate, and no longer coordinates any of the metal ions.	
<b><i>Mycobacterium tuberculosis</i></b>	2004	Crystal structure of <i>MtDut</i> reveals that its binding pocket is similar to that of <i>hDut</i> , hampering the design of <i>MtDut</i> specific inhibitors. Tris molecule in the trimer channel interface might be an inhibitor lead.	[12]
	2008	Identification of a bifunctional dCTP deaminase dUTPase in <i>M. tub.</i> Lower similarity to <i>hDut</i> and broader substrate specificity than <i>MtDut</i> marks this enzyme a possible target for chemotherapy.	[28]
	2008	Introducing a highly sensitive fluorescent label to follow the <i>MtDut</i> enzymatic reaction. Structure and activity of H145W <i>MtDut</i> is not altered.	[14]
	2011	Molecular modeling of <i>MtDut</i> nucleotide binding, based on activation energies from QM-MM modeling hydrolysis is slower than product release.	[29]
	2012	The dUTPase enzyme is essential in <i>Mycobacterium smegmatis</i> . Mycobacteria-specific loop has no major effect on <i>MtDut</i> activity <i>in vitro</i> , but a loop-specific function seems to be essential within the <i>in vivo</i> model <i>M. smegmatis</i> .	[17]
	2015	Virtual screening of several million small molecules against the species-specific surface loop of <i>MtDut</i> was performed. An optimized hit was conjugated to a phagocytosis stimulating tuftsin peptide derivative and encapsulated into PLGA nanoparticles. <i>In vivo</i> efficacy of this formulation was verified in guinea pig model.	[15]
	2016	The prevention of DNA uracilation and the regulation of dNTP balance are decoupled in Mycobacteria and separately achieved by <i>Dut</i> and <i>Dcd:dut</i> enzyme functions, respectively.	[30]
<b><i>Plasmodium falciparum</i></b>	2005	Development of selective inhibitor leads against <i>PfDUT</i> with antiparasite activity. Crystal structure of inhibitor bound <i>PfDut</i> .	[13]
	2005	Selective, nontoxic, drug-like inhibitor lead design against <i>PfDut</i> . Analogues of dUMP with variety of substituents at the 5'- and 3'-positions. Effectivity is not sufficient against <i>Leishmania</i> and <i>Trypanosoma</i> parasites.	[31]
	2006	Acyclic uracil derivatives with similar or better antiplasmodial properties than those in Ref [31] especially with regards to selectivity. $K_i$ of best active compound was 0.2 $\mu$ M.	[32]
	2007	Study of <i>PfDut</i> ligand binding. No significant conformational changes upon binding are inferred based on ITC measurements.	[33]
	2009	Tritylated uracil acetamide derivatives containing amide bond between the $\beta$ -C and N-1 of uracil ring were found to be weak inhibitors of the <i>PfDut</i> .	[34]
	2010	Study on <i>PfDut</i> and <i>hDut</i> kinetics. Specific product inhibition of the Plasmodium dUTPase compared to the human enzyme, was caused by the substituent at the C-5 position of the uracil ring.	[35]
	2011	<i>In vitro</i> HTS for <i>PfDut</i> inhibitors in a 3086 item compound library of commercially available non-proprietary compounds did not identify any hits.	[18]
	2011	Modification on the uracil ring of the tested compounds impaired inhibitory	[36]

		effect of those on <i>Pf</i> Dut. While there is room for variation of the 5'-trityl group and the 3'-substituent.	
	2011	Testing $\beta$ -branched acyclic uridine analogues as <i>Pf</i> Dut inhibitors. $K_i$ of the best inhibitor was 0.5 $\mu$ M. This showed more than 200-fold selectivity compared to <i>h</i> Dut and $EC_{50}$ = 0.61 $\mu$ M growth inhibition of <i>P. falciparum</i> .	[20]
	2011	Mutational analysis of residues important in binding of uracil based inhibitors containing trityl groups at the 5'-position. F46A mutation of <i>Pf</i> Dut leads to an increase in $K_i$ values while K96A mutation has an opposite effect.	[19]
	2011	Testing lower lipophilicity and molecular weight diphenyl substituted inhibitors of <i>Pf</i> Dut. Slightly decreased activity against both dUTPase and parasite than the corresponding trityl derivatives was observed.	[37]
	2013	Characterization of novel conformationally restrained amide derivatives to overcome entropic disadvantages of former <i>Pf</i> Dut inhibitors. Inhibitors showed similar or greater potency but lower selectivity (<40x) in cellular assays, than the previous drug candidates against <i>Pf</i> Dut.	[38]
	2015	2D- and 3D-QSAR model using the LQTA-QSAR methodology on a series of <i>Pf</i> Dut inhibitors with high predictive power facilitates the design of new compounds with higher antimalarial bioactivities.	[21]


212

213

## 2. Inhibition of thymidylate synthases

Thymidylate synthase enzymes can be divided to two distinct categories: the so-called “classical” (TS) and flavin-dependent (ThyX) enzymes (Figure 3). These two types of thymidylate synthase enzymes share no mechanistic and structural similarity, however they perform the same enzymatic function (an interesting parallel to the two families of dUTPases, trimeric and dimeric). The flavin-dependent ThyX catalyzes FAD mediated methyl group addition to dUMP from 5,10-methylene tetrahydrofolate ( $\text{CH}_2\text{THF}$ ), resulting in dTMP and tetrahydrofolate in prokaryotes [39]. Recovery of  $\text{CH}_2\text{THF}$  from the reaction products is performed by serine hydroxymethyltransferase. In contrast, in case of the classical thymidylate synthases (TSs), which are the product of gene *tymS* in eukaryotes and gene *thyA* in prokaryotic systems (often referred as ThyA), the methyl group is directly transferred from  $\text{CH}_2\text{THF}$  to dUMP and the resulting dihydrofolate is recycled through the consecutive action of dihydrofolate reductase and serine hydroxymethyltransferase. The “classical” enzymes can be divided into two subgroups since some of those are bifunctional DHFR-TSs (Figure 3), although the TS domains of the bifunctional enzymes are highly similar to monofunctional TSs in terms of structure and catalytic mechanism. As a consequence of key importance of both kinds of thymidylate synthases in thymidine biosynthesis, those are subjects of extensive inhibitor design programs.





**Figure 3. Comparison of catalytic mechanism and structure of different thymidylate synthases.** **A)** Classical thymidylate synthase reaction cycle **B)** Structure of *M. tuberculosis* classical thymidylate synthase – *Mt*TS (PDB ID: 4FOX) Protein is in cartoon representation, monomers colored cyan and salmon. dUMP and folate analogue inhibitor raltitrexed represented as sticks with atomic coloring (carbon: black, oxygen: red, phosphorus: orange, nitrogen: blue). Close up enlightens the ligand binding orientation. **C)** Structure of *Ch*DHFR-TS (PDB ID: 4Q0D). Protein is in cartoon representation, TS domains with cyan and salmon, the corresponding DHFR domains with yellow and green. 5F-dUMP, and folic acid analogue 2XB (from Ref [40]) represented as sticks with atomic coloring (carbon: black, oxygen: red, phosphorus: orange, nitrogen: blue). Close up enlightens ligand binding orientation. **D)** ThyX mechanism according to ref. [39]. **E)** *Thermotoga maritima* ThyX (PDB ID: 4GT9) Protein is in cartoon representation, subunits of the tetramer colored cyan, blue, magenta and salmon. dUMP, CH<sub>2</sub>THF substrates and FAD cofactor represented as sticks with atomic coloring (substrate carbon: black, cofactor carbon: yellow, oxygen: red, phosphorus: orange, nitrogen: blue) To ease visualization, substrates from only two substrate binding pockets are shown. Close up enlightens ligand binding orientation of one of the active sites.



## 2.1. Inhibitors of classical thymidylate synthases

Although the structure of the “classical” thymidylate synthases is highly conserved, several drug design programs still attempt to exploit the slight differences between pathogenic and human enzymes to design selective inhibitors of parasite TSs (Table 3).

Comparing the structures of TS enzymes from bacteria and human it can be concluded that the conformation adopted by the enzymes upon binding of dUMP and folate-analog inhibitors is analogous [41]. The difference in the degree of active site closure could be a key to discriminate bacterial TSs against eukaryotic TSs and may provide basis for the design of species-specific non-folate analogues [41]. Towards this end *Lactobacillus casei* thymidylate synthase was studied as a model for TS enzymes from pathogens such as *Enterococcus faecalis*, *Staphylococcus aureus* and *Bacillus anthracis*, since the dimer interface loop region of these proteins is highly similar and both contain a small domain of fifty amino acids (residues 90-139 in *LcTS*), which is not present in the *E. coli* and human TSs [42–44].

First studies identified phenolphthalein and its derivatives as *LcTS* inhibitors with micromolar activity [45–47]. Extending the phthalimidic core resulted in 1,8-, 2,3- naphthalein compounds binding to *LcTS* at sub-micromolar concentrations while showing no detectable affinity for the human enzyme [48]. Several of these derivatives also showed selective antibacterial activity against other bacteria, such as *S. aureus*, *Streptococcus* and *Cryptococcus neoformans* in cell culture assays [49]. Nonetheless, crystal structures of complexes of *C. neoformans* and *E. coli* enzymes with one of the best active compounds did not provide a clear explanation for the origin of selectivity [50].

In parallel to these studies dansyl-tyrosine derivatives with micromolar affinities to bacterial TSs were identified as promising leads for drug design [51]. These compounds exploit the flexibility of the folate-binding site of bacterial TSs and possess enhanced specificity because of the interactions formed with non-conserved residues outside the active site of the bacterial enzymes [43,52].

Subsequent development programs were focused only on the enhancement of the affinity and specificity of the naphthalein series. Optimization resulted in 1,2-naphthalein derivatives showing significant and dose dependent antibacterial potency against *Staphylococcus epidermidis* clinical isolate strains, without any signs of *in vitro* host toxicity and was also potent against *Enterococcus faecalis* and *Staphylococcus aureus* [53]. Importantly, the bacterial strains in this study were resistant to most of the best known antibacterial drugs,

including vancomycin, hence this inhibitor can be regarded as a promising future antibacterial agent [53].

Since the observed multiple binding modes of these naphthalein derivatives significantly impeded structure-based drug design, recent studies aimed to find inhibitors displaying a unique binding mode [54]. Therefore, starting from phenolphthalein, and following a retrosynthetic approach two compound libraries of two different scaffolds were designed [54]. X-ray crystallographic screening of the greatest potency hits revealed that some of those present in a common unique binding mode. Further improvement of these initial hits resulted in carboxamide derivatives with moderate, albeit specific potency against *EcTS* [55]. Following this deconstruction approach, drug design studies starting from a complex *hTS* inhibitor led to compounds, which displaced dUMP from its classical active site position in the ternary complex. One of these inhibitors showed  $K_i=0.31\mu\text{M}$ , and more than twenty-fold selectivity against *PcTS* [56]. Initial hits for the *Enterococcus faecalis* TS enzyme are also reported in the same study, which could be optimized in the future based on the recently published crystal structure of *EfTS* [57]. In addition the fact that 5-formyltetrahydrofolate co-purifies with *EfTS* from cell extract and is observed at the active site of *EfTS* in the crystal structure raises fundamental questions about how the folate and thymidylate biosynthesis are coupled and regulated in these bacteria [57].

The thymidylate synthases of protozoan parasites like Plasmodia and Trypanosoma are fused to dihydrofolate reductase forming a bifunctional enzyme. In these cases drug development focuses mostly on DHFR inhibition (see section 3.2.).

304 **Table 3.** Recent results on the inhibition of classical thymidylate synthases (TS)

Organism	Year	Summary	Ref.
<i>Lactobacillus casei</i>	1999	Several crystal structures of <i>Lc</i> TS bound to dUMP and phthalimidic derivatives, which are designed to selectively inhibit TS enzymes of pathogenic species.	[48] [49]
	1999 2001	Structure-based design of dansyl-tyrosine derivatives, which specifically inhibit bacterial TSs, possibly due to interactions formed with non-conserved residues close to the active site.	[51] [52]
	2005	Molecular dynamics simulations explaining activity and species-specificity of the best active compound from Ref [51] based on the predicted binding mode of the inhibitor to <i>Lc</i> TS.	[43]
	2008	Changing the rigidity of dansyl-tyrosine derivatives oppositely alters effectivity of those against <i>Lc</i> TS and <i>Ec</i> TS.	[58]
	2011	Retrosynthetic method to design novel compounds exhibiting unique binding modes to <i>Lc</i> TS led to promising candidates having single binding orientation.	[54]
<i>Pneumocystis carinii</i>	2000	Based on the crystal structure the fungal specific $\beta$ -sheet and the greater size of the active site of <i>Pc</i> TS can be exploited for specific antifungal drug design.	[47]
	2003	Greater flexibility of parasite TSs compared to eukaryotic enzymes allow the design of specific antiparasite agents.	[41]
	2013	Following of a deconstruction synthesis approach starting from a complex <i>h</i> TS inhibitor resulted in novel specific inhibitors of <i>Pc</i> TS with low micromolar affinity (best compound showed $K_i$ of 0.31 $\mu$ M and more than 20-fold selectivity).	[56]
<i>Enterococcus faecalis</i>	2006	In an extensive antibacterial TS inhibitor study a 1,2-naphthalein derivative proved to have MIC of 2.5 $\mu$ g/mL against <i>E. faecalis</i> .	[53]
	2011	Identification of a benzonitrile substituted dioxo-isoindol derivative as a good initial candidate for <i>Ef</i> TS inhibitor design.	[54]
	2012	The crystal structure of <i>E. faecalis</i> thymidylate synthase serving as a basis of specific inhibitor development. 5-formyltetrahydrofolate found at the active site of <i>Ef</i> TS introduces questions about the connections between the folate and thymidylate biosynthesis in <i>E. faecalis</i> .	[57]
	2013	A retrosynthetic inhibitor design starting from a complex <i>h</i> TS inhibitor resulted in only moderately potent drugs against <i>Ef</i> TS.	[56]
<i>Staphylococcus aureus</i>	2006	Several 1,2- and 1,8-naphthalein acting as TS inhibitors were proven to have MIC of 0.5-5 $\mu$ g/mL against <i>S. aureus</i> .	[53]
<i>Staphylococcus epidermidis</i>	2006	During a thorough antibacterial TS inhibitor study a 1,2-naphthalein derivative showing significant and dose dependent potency against <i>S. epidermidis</i> clinical isolate strains was identified.	[53]

## 2.2. Inhibitors against flavin-dependent thymidylate synthase, ThyX

ThyX, a thymidylate synthase with drastically different active-site geometries and distinct enzymatic mechanisms as compared to the classical TS isoenzymes, has been discovered in 2002 [59–61]. The flavin-dependent ThyX applies a unique chemical cascade that does not follow the general scheme of biological methylation, but uses the following steps instead: i) activation of the nucleotide that involves no covalent modification but only electrostatic polarization of dUMP by the enzyme's active site ii) methylene transfer from folate mediated by N5 of FAD [39] (Figure 3). As a consequence of the marked alterations in chemical mechanism from that of the classical thymidylate synthases along with the observed structural differences, inhibitors of classical TSs have only a reduced effect on ThyX enzymes [62–65].

The exclusive existence of a distinct class of thymidylate synthase in a plethora of major pathogenic microorganisms including also *Bacillus anthracis*, *Clostridium botulinum*, *Mycobacteria* and *Treponema pallidum*, opened a new horizon for developing of antibiotic inhibitors with reduced toxicity [66] (Table 4). The emergence of mutations diminishing the effectivity of classical antifolate drugs against classical TSs of these organisms also underlines the high relevance of this novel approach [67]. Mutational studies showing that ThyX, but not the classical TS is essential in *M. tuberculosis* also supports the validity of the flavin-dependent enzyme as a drug development platform [68].

Structure based design is aided by crystal structures of ThyX enzymes from several species [62,65,69–75]. Extensive studies on numerous substituted deoxyuridine monophosphate derivatives resulted in drugs that clearly distinguished between *MtThyX* and *MtTS* and showed, albeit moderate, inhibition on *MtThyX*, but not on *MtTS*. However, some of these drugs also possessed dual potency being active against *MtTMPK* as well [76–80]. High throughput screens for non-substrate analogue inhibitors of ThyX activity, using *Paramecium bursaria chlorella virus* (PCBV)-1 ThyX, a well-studied model for flavin-dependent thymidylate synthases [63,81,82], resulted in several selective inhibitors of *MtThyX* and *HpThyX* [83]. One of these, namely 2-bromo-8-hydroxy-1,4-naphthoquinone also showed cellular activity against genetically modified *E. coli* strains in which the chromosomal copy of TS was replaced by PBCV-1 ThyX. Further derivatization of this compound led to drug molecules displaying high potency against *Helicobacter pylori* ThyX and showing also modest, but significant activity in an animal infection model [84]. Since other similar

338 naphthoquinone derivatives have already passed clinical trials this scaffold seems to be very  
339 promising target for ThyX inhibitor design [83].

340 **Table 4.** Recent results on the inhibition of flavin-dependent thymidylate synthase (ThyX)

Organism	Year	Summary	Ref.
<i>Thermotoga maritima</i>	2003	Crystal structure of <i>TmThyX</i> reveals an common fold of ThyX family.	[62]
	2012	X-ray crystal structures of <i>TmThyX</i> with several folate derivatives are serving as useful models for drug design. The previously proposed mechanism of arginine mediated methylene transfer was eliminated by study of mutant R174K <i>TmThyX</i> enzymes.	[73]
	2013	Conformational change is essential for substrate binding of <i>TmThyX</i> . Compounds locking open conformation of the substrate-binding loop might act as specific inhibitors.	[74]
<i>Paramecium bursaria chlorella virus-1</i>	2004	Analysis of FAD-dependent thymidylate synthase ThyX from PBCV supports that ThyX-specific inhibitors that do not affect classical TS enzymes can be designed.	[63]
	2006	Conformation of key residues at the active site of PBCV-1 ThyX differs from earlier reported ThyX structures, suggesting structural changes during catalysis. The reaction proceeds without methylene enzyme formation.	[81]
	2007	Report on benzoyl and triazole derivatives that demonstrated inhibition of the catalytic activity of PBCV1 ThyX.	[82]
		2-hydroxy-1,4-naphthoquinone derivatives (1,4-NQs) are tight binding inhibitors of PBCV-1 ThyX <i>in vitro</i> and <i>in vivo</i> .	[83]
	2014	Orchestrated fast reactions of the native substrates of ThyX, bypasses NADPH oxidase activity during the enzymatic reaction in aerobic microorganisms, enabling effective ThyX activity in oxygen rich cellular milieu.	[85]
<i>Mycobacterium tuberculosis</i>	2004	<i>MtTS</i> mutations represent a pathway for development of antifolate drug resistance.	[67]
	2005	Crystal structure of <i>MtThyX</i> . ThyX enzymes are strongly conserved amongst evolutionarily distant organisms based on structural, functional and genomic comparisons.	[69]
	2006	Soaking of the crystal containing <i>MtThyX</i> -FAD-BrdUMP ternary complex into NADP <sup>+</sup> solution results instead of a quaternary complex in a binary complex of NADP <sup>+</sup> and Br-dUMP. For implication of data detailed mechanistic studies are required.	[70]
	2008	Extensive mutational study reveals a serine and a histidine as the key residues of <i>MtThyX</i> enzyme activity. It is still unclear which residues contribute to binding of methylenetetrahydrofolate (MTHFR) and NADPH.	[86]
	2008	Study of <i>MtTS</i> and <i>MtThyX</i> kinetics shows that both enzymes have low catalytic activity. A folate-based inhibitor revealed high selectivity against <i>MtTS</i> over <i>MtThyX</i> , entailing the possibility that reciprocal inhibitors of <i>MtThyX</i> may exist.	[64]
	2011	Testing substituted 2'-deoxyuridine monophosphate analogues against <i>MtThyX</i> .	[76]

		Best compound showed $IC_{50}=0.91 \mu M$ and lacked activity against <i>MtTS</i> ( $IC_{50} > 50 \mu M$ ).	
	2012	Identification of weak <i>MtThyX</i> inhibitors, which exhibited no activity against <i>MtTS</i> Compounds were either substrate or inhibitor of <i>MtTMPK</i> , this simultaneous action might be advantageous for drug design.	[77]
	2012	2-hydroxy-1,4-naphthoquinone derivatives (1,4-NQs) inhibit the activity of <i>MtThyX</i> and <i>HpThyX</i> , but not that of <i>hTS</i> . Other 1,4-NQs have passed clinical trials, which designates this scaffold a very promising target for ThyX inhibitor design.	[83]
	2013	5-alkynyl uridine analogues in which the sugar moiety has been replaced by an acyclic phosphonate were designed against <i>MtThyX</i> based on binding model from NMR data. Weak inhibition of ThyX is achieved (43% inhibition at $50 \mu M$ inhibitor concentration).	[78]
	2015	C-5 modified nucleosides with antimycobacterial activity were tested against thymidylate synthases of <i>M.tub</i> . These showed lack of activity against the <i>MtTS</i> , while $IC_{50}$ of the best compound against <i>MtThyX</i> was $8.32 \mu M$ . Mechanism of action of these compounds could only partially be associated with the inhibition of <i>MtThyX</i> .	[79]
	2015	Inhibition of <i>MtThyX</i> by 5-FU is contributing to the mechanism of anti-mycobacterial action of this drug.	[87]
	2015	High throughput crystallization of <i>M. tuberculosis</i> proteins resulted in structures of <i>MtThyX</i> bound to FAD and FdUMP deposited in the PDB.	[75]
	2016	Mechanism of ThyX action fundamentally differs from that of classical TSs. The folate in this case transfers the methyl group not directly to dUMP but to the flavin cofactor. This is a hitherto unseen methylation scheme.	[39]
<i>Helicobacter pylori</i>	2002	Identification of the first flavin-dependent thymidylate synthase in <i>H. pylori</i> .	[59]
	2004	Based on a mutational study Ser 84 in <i>HpThyX</i> is responsible for dUMP activation.	[60]
	2011, 2012	Crystal structures and characterization of <i>HpThyX</i> enzyme aiding species specific drug design.	[71] [72]
	2015	2-hydroxy-1,4-naphthoquinone derivatives display potent inhibition of <i>HpThyX</i> activity. One of these has shown modest, but significant activity in an animal infection model.	[84]

### 3. Dihydrofolate reductase inhibitors

Dihydrofolate reductase is a well-validated therapeutic target of the folate pathway. There exist two major groups of these enzymes: the monofunctional DHFR and bifunctional DHFR-TS enzymes.

#### 3.1. Monofunctional DHFR

Currently extensive studies are in progress against DHFRs of *Pneumocystis* and *Mycobacteria* since these parasites lack thymine salvage pathway and rely solely on *de novo* synthesis of this pyrimidine base [11,88] (Table 5). However, DHFRs of other pathogens also seem to be effective and highly studied targets (Table 5).

##### 3.1.1. *Pneumocystis carinii*

The high resolution crystal structure of *Pc*DHFR initiated structure-based inhibitor design against this enzyme [89]. Starting from piritrexim by replacing the carbon linker (C9) to nitrogen and adding a methyl group to form a triamine resulted in series of pyrido-pyrimidine compounds with enhanced selectivity against *Pc*DHFR and *Tg*DHFR-TS [90]. Structure analysis confirmed that this N9-methyl group interacts more favorably with Ile123 present at the substrate binding site of *Pc*DHFR than with Val115, which resides at the same place in *h*DHFR [91]. Although optimization of the substituents of the phenyl ring attached to N9 resulted in compounds with enhanced selectivity against both *P. carinii* and *P. jirovecii* DHFRs [92], the structure activity relationship is not fully apparent based on the enzyme-inhibitor co-crystal structures [91]. Similar diaminoquinazoline derivatives in spite of showing higher effectivity were proven to be less selective against parasitic DHFRs as compared to pyrido-pyrimidines [93,94]. Studies of compounds with the arylthio-substituted furo-pyrimidine scaffold resulted in inhibitors with improved selectivity, however inadequate cellular uptake of these drugs prevented their further development [95]. This clearly indicates that studies on bacterial cell cultures and human cells assessing whole cell activity and toxicity are necessary to fully evaluate drug candidates against *Pneumocystis* species.



### 3.1.2. *Bacillus anthracis*

The resistance of *B. anthracis* against trimethoprim promoted research for a potent inhibitor of DHFR of this bioterrorism agent parasite [96]. Testing of numerous classes of compounds resulted in some promising potent and selective hits [97,98], while some propargyl-derivatives were turned out to be potent but not selective inhibitors of *Ba*DHFR [99]. Structural information from crystallographic, NMR and mutational studies [100–102] combined with systematic analysis of substituents on the 2,4-diaminopyrimidine scaffold led to compounds with improved potency and selectivity against *Ba*DHFR [103–109]. It has also been shown that efficiency can be further enhanced by applying the favored enantiomer instead of a racemic mixture of active compounds [106,109].

### 3.1.3. *Enterococcus faecalis*

In case of *E. faecalis* the first studies about inhibitors against *Ef*DHFR were recently published [110]. Investigation of 2,4-diaminopyrimidine derivatives proven to be active against *Ba*DHFR [104], revealed that those are also potent inhibitors of *Ef*DHFR. Modeling studies concluded that propargyl linked compounds may even be more suitable inhibitors of DHFR mutant *E. faecalis* strains. Since the mutation causing steric clash in case of other inhibitors does not affect these derivatives because of their better fit to the active site pocket of the dihydrofolate substrate [110].

### 3.1.4. *Staphylococcus aureus*

The first line therapy of community-associated methicillin-resistant *Staphylococcus aureus* (CA MRSA) is a combined formulation under the brand name Bactrim targeting the folate biosynthesis of the bacteria, containing trimethoprim, a dihydrofolate reductase inhibitor and sulfamethoxazole, which is a dihydropteroate synthase inhibitor. However, emergence of DHFR mutations leading to trimethoprim resistant strains necessitates the development of novel inhibitors that effectively act against these mutant *Sa*DHFRs to prolong the applicability of this class of antibiotics. Derivatization of trimethoprim resulted in a 5-benzyl-2,4-diaminopyrimidine, Iclaprim, which showed favorable antibacterial activity on TMP-resistant *Staphylococcus aureus* strains, and has reached phase 3 trials [111,112]. However these trials for the treatment of hospital-acquired, ventilator-associated, or health-care-

associated pneumonia were terminated due to financial resource limitations<sup>1</sup>. Other 2,4-diaminopyrimidine compounds proven to be effective inhibitors of *B. anthracis* DHFR were also tested against *S. aureus*. In spite of their favorable anti-staphylococcal potency, these leads were optimized later only against *Ba*DHFR [105,113].

Propargyl-linked compounds with the same diaminopyrimidine scaffold, targeting DHFRs of various parasites were also optimized against *Sa*DHFR [99,114,115]. These studies resulted in active and selective inhibitors of both wild-type and a TMP-resistant mutant enzyme [116–120]. Based on these experiences development of inhibitors of Gram-negative bacteria, *Klebsiella pneumoniae* DHFR is also in the pipeline [121].

Derivatives containing the 2,4-diaminoquinazoline scaffold known for their high potency on *Pc*DHFR and *Trypanosomal* DHFR-TSs [93,94,122], were parallelly developed against *S. aureus* and *Mycobacteria*. The inhibitors designed during this project were also very promising candidates for future therapies targeting *Sa*DHFR [123,124]. However high serum binding of these compounds may decrease their *in vivo* efficacy. Recent *in silico* screening studies resulted in completely new scaffolds with favorable *in vitro* potency, initiating a new line of *Sa*DHFR inhibitor design [125].

Recently it has been shown that exposure of DHFR targeting drugs induced hypermutator thymine auxotroph mutants [126,127], in which acquiring of antibiotic resistance was significantly more prevalent [128]. These phenomena might raise debates about the use of DHFR therapeutic pathway against *S. aureus*.

### 3.1.5. *Streptococcus mutans*

Trimetrexate analogues were identified as very potent inhibitors of *S. mutans* DHFR, a derivative with enhanced selectivity potentially impaired cell growth and formation of *S. mutans* biofilms [129].

### 3.1.6. *Mycobacterium tuberculosis*

In addition to the extensive efforts against *Mycobacterial* ThyX, classical DHFR inhibition is still applied against *Mycobacteria*. This approach is supported also by a recent verification of DHFR as a target of one of the first antituberculosis agents, para-aminosalicylic acid (PAS), a prodrug that after being activated by the folate pathway inhibits *Mt*DHFR [130,131].

<sup>1</sup> <https://clinicaltrials.gov/ct2/show/NCT00543608?term=NCT00543608&rank=1>

In this case however, it is questionable if *Mt*DHFR inhibition acts *via* inducing thymineless cell death [132], since it has been proven that the flavin-dependent ThyX can provide enough dTMP for normal bacterial growth in a classical thymidylate synthase (*Mt*TS) deficient strain [68], bypassing the need of *Mt*DHFR. As an alternative explanation, disruption of the reactions centered around S-adenosylmethionine is suggested to be a primary cause of lethality of *Mt*DHFR inhibitors [132]. This is also concordant with a model explaining resistance of *M. tuberculosis* cell lines defective in *Mt*TS function to PAS, an inhibitor of *Mt*DHFR [68,133]. In these mutant bacteria, more reduced folates remain available for other essential one-carbon addition reactions, which results in increased bacterial survival [131]. However, further studies are required to fully resolve this question.

As PAS-resistant DHFR mutant *M. tuberculosis* strains are emerging and since PAS toxicity leads to gastrointestinal ailments, it is of great importance to find alternative *Mt*DHFR inhibitors [134–137].

First trials against *Mt*DHFR applied 1,6-dihydro-2,4-diamino-1,3,5-triazin derivative (WR99210) and its analogues, which have been proven to be potent against *Mycobacterium avium* [138]. These compounds were active in cellular assays, but unfortunately showed high toxicity in host cells which prevented their further development [139]. Aiming to identify inhibitors with better profiles certain studies hypothesized that filling the glycerol binding pocket observed in the crystal structures of human and *M. tuberculosis* DHFR by the inhibitor will enhance both potency and selectivity [140–142]. Pyrimethamine analogues with the triol-mimicking trihydroxypentyl group were proven to be potent against *Mt*DHFR [141], however no report is available about effects of those on *M. tuberculosis* growth. It is plausible that this hydrophilic modification prevents these hits to penetrate through the waxy mycobacterial cell wall, based on the fact that the inverse, lipophilic modification of methotrexate dramatically increased the whole-cell activity of the original molecule [132].

Recently, a 2,4-diaminoquinazoline fragment was identified in a HTS search and was derivatized based on trimetrexate to have enhanced antimycobacterial potency [139,143]. Promising hits were also found amongst the compounds with 2,4-diamino-triazin and tetrahydro-1,3,5-triazin-2-amine scaffolds [144–147].

The vast number of recent reports about inhibitor research against *Mt*DHFR indicates that the extensive work has not yet resulted in a fully adequate candidate against this target. Further

drug development will hopefully lead to novel therapeutic agents to fight against drug resistant *Mycobacterial* species.

### 3.1.7. *Candida* species

While the TS enzyme of *Candida* species is not yet covered in literature, DHFR inhibitors were tested and fine-tuned against these fungi. The first potent inhibitors against *Ca*DHFR were 1,3-diaminopyrrolo-quinazolines, which although being very effective both *in vitro* and *in vivo* were proven to be even more active against *h*DHFR [148]. In parallel the thorough optimization of 2,4-diaminopyrimidines resulted in a family of propagyl-linker containing derivatives, which are potent and selective inhibitors of *Cg*DHFR and *Ca*DHFR with significant antifungal effects and low host cell toxicity [115,149–154]. Nevertheless finding an adequate explanation for the observed inconsistencies between target inhibition and antifungal activity of these compounds in case of *C. albicans* [154] is of utmost importance for the future drug development programs. Still it is worth revisiting previously dismissed *Ca*DHFR inhibitor leads with moderate *in vitro* activity, since it is possible that those have sufficient antifungal potency [154]. Recent modeling studies present a validated inverse docking method for compound selectivity prediction, which could also promote the development of these antifungal DHFR inhibitors [155].

474 **Table 5.** Recent results on the inhibition of monofunctional dihydrofolate reductases (DHFR)

Organism	Year	Summary	Ref.
<i>Pneumocystis carinii</i>	2008	Methyl or ethyl substitution of the linker N9 atom of the 2,4-diaminoquinazoline inhibitors enhanced the potency of those. The original low selectivity of the compounds was unaffected.	[94]
	2010	Compounds having the arylthio-substituted furo-pyrimidine scaffold resulted in <i>Pc</i> DHFR inhibitors with improved selectivity, however these classical folates can not enter to <i>P. carinii</i> cells due to lack of transfer apparatus.	[95]
	2013	2,4-diaminopyrimidine derivatives methylated at the N9 linker were highly active and selective inhibitors of <i>P. jirovecii</i> and <i>P. carinii</i> DHFRs <i>in vitro</i> .	[92]
	2015	Enhanced potency and selectivity of the best compounds from Ref [92] is due to van der Waals interactions of the N9-methyl group at the active site. These are more favorable between Ile123 (present in both <i>Pc</i> DHFR and <i>Pj</i> DHFR) than those with the corresponding Val115 in <i>h</i> DHFR. Overall structure–activity correlations of inhibitors are less evident.	[91]
<i>B. anthracis</i>	2006	2,4-diamino-5-deazapteridine and pyrimidine derivatives showed <i>in vitro</i> activities against <i>Ba</i> DHFR and effectively impaired growth of <i>B. cereus</i> . Selectivity of these inhibitors is to be enhanced.	[97]
	2007	2,4-diaminopyrimidine derivatives, attached to a dihydrophthalazine ring showed high potency and selectivity against <i>Ba</i> DHFR and were also active against <i>B. anthracis</i> Sterne. Best compound referred later as RAB1.	[98]
	2007	Crystal structure of <i>Ba</i> DHFR provides an accurate pharmacophore for structure based design of inhibitors.	[100]
	2008	Propargyl-linked 2,4-diaminopyrimidine derivatives were active against <i>B. anthracis</i> Sterne and potent but not selective inhibitors of <i>Ba</i> DHFR.	[99]
	2009	Structure of <i>Ba</i> DHFR in solution based on NMR measurements reveals flexible parts of the active site.	[101]
	2009	Crystal structure <i>Ba</i> DHFR with RAB1 serves as structural foundation for development of derivatives with enhanced properties.	[103]
	2010	Identification of important active site contacts of <i>Ba</i> DHFR inhibitors in a mutational and crystallographic study.	[102]
	2012 2014	Derivatives with various substituents at the dihydrophthalazine moiety of RAB1 showing no major difference in potency and selectivity.	[104] [107]
	2013	Substitutions at the C6 position of the 2,4-diaminopyrimidine scaffold of RAB1 lead to compounds with attenuated potency against <i>Ba</i> DHFR.	[105]
	2013	S-enantiomers of potent propargyl-linked 2,4-diaminopyrimidines inhibitors are more active against <i>Ba</i> DHFR. Concentration of S-stereoisomer diluted by the R-enantiomer is to be considered during activity studies.	[106]
	2015	Identification of RAB1 sites which are sensitive to modification, substitution at these positions led to reduced potency.	[108]
	2015	Studies on derivatives with various substituents at the dihydrophthalazine moiety of RAB1 showed that compounds with allyl and vinyl substituents are significantly more potent than RAB1 both <i>in vitro</i> and <i>in vivo</i> .	[109]
<i>Enterococcus</i>	2014	RAB1 analogues are potent inhibitors of <i>Ej</i> DHFR and have promising	[110]

<i>faecalis</i>		whole-cell activity. Based on modeling results propargyl-linked inhibitors can be effective against <i>E</i> /DHFR mutants because those fit tighter to the site of the folate substrate.	
<i>Staphylococcus aureus</i>	2009	F98Y mutation in <i>Sa</i> DHFR may be responsible for trimethoprim resistance through making favorable a second position for cofactor binding, which impedes inhibitor binding.	[116]
	2010 2013	<i>B. anthracis</i> inhibitor 2,4-diaminopyrimidine-dihydrophthalazine derivatives were potent against <i>Sa</i> DHFR and presented anti-staphylococcal activity. No report on further optimization of these compounds against <i>S. aureus</i>	[113] [105]
	2011	Structure-based design of 2,4-diaminoquinazoline derivatives against <i>Sa</i> DHFR resulted in potent inhibitors with adequate antibacterial activity. Selectivity of the compounds is to be enhanced.	[123]
	2012	Propargyl-linked 2,4-diaminopyrimidines proved to be active against several parasites were fine-tuned against MRSA and <i>S. pyogenes</i> by the incorporation of additional pyridyl-heterocycles. The resulting potent inhibitors of <i>Sa</i> DHFR and <i>Sp</i> DHFR were also active against clinical isolates of several antibiotic resistant <i>Staphylococcal</i> strains.	[117]
	2012	Resistance mutations in <i>Sa</i> DHFR were induced by propargyl-linked 2,4-diaminopyrimidine derivatives with moderate frequency. Effectivity of these inhibitors decreased by the mutations however the resulting MICs are still acceptable (2.5 µg/ml).	[118]
	2013	Crystal structures of <i>h</i> DHFR with propargyl-linked 2,4-diaminopyrimidines of high antibacterial potency serve as a basis for selective inhibitor design.	[119]
	2014	Attaching a 7-substituted-benzimidazol-1-yl moiety to the 2,4-diaminoquinazoline scaffold led to highly selective <i>Sa</i> DHFR inhibitors with great potency against <i>S. aureus</i> . High serum binding might significantly reduce the level of <i>in vivo</i> efficacy of these compounds.	[124]
	2014	Multiple virtual screenings of large compound libraries for <i>Sa</i> DHFR inhibitors resulted in hits with promising anti-staphylococcal properties. Those were found to be active against <i>Sa</i> DHFR but not toxic against mammalian cells. Development of these novel scaffolds is in progress.	[125]
	2015	Potency of enantiomers of propargyl-linked 2,4-diaminopyrimidine derivatives against <i>Sa</i> DHFR is significantly different from each other.	[120]
	2015	Trimethoprim-sulfamethoxazole antifolate therapy triggers <i>Sa</i> TS mutations leading to thymine-dependent small colony variant formation, which is less virulent, but more persistent than the wild type bacteria.	[127]
<i>Klebsiella pneumoniae</i>	2014	Propargyl-linked 2,4-diaminopyrimidine derivatives inhibit <i>Kp</i> DHFR and impair <i>Klebsiella pneumoniae</i> cell growth. Crystal structures of <i>Kp</i> DHFR with these compounds will aid the design of compounds with enhanced selectivity.	[121]
<i>Streptococcus mutans</i>	2014	Identification of trimetrexate analogues against <i>Sm</i> DHFR resulted in compounds, which selectively (SI>100) inhibited cell growth and formation of <i>S. mutans</i> biofilms.	[129]
<i>Mycobacterium tuberculosis</i>	2000	Inhibitor bound three-dimensional structure of <i>Mt</i> DHFR aids structure based drug design against this target enzyme.	[140]
	2002	First proof that besides being active against <i>M. avium</i> the dihydro-	[138]

		diamino-triazin derivative WR99210 potently impairs <i>M. tuberculosis</i> cell growth via <i>MtDHFR</i> inhibition.	
	2007	Pyrimethamine analogues having triol substituents accommodating the glycerol binding site of <i>MtDHFR</i> were proven to be potent inhibitors of the enzyme.	[141]
	2012	A 2,4-diaminoquinazoline fragment was identified in a HTS project as a potent <i>MtDHFR</i> inhibitor and showed promising target specific effects in cellular assays.	[139]
	2013	Antimalarial drug para-aminosalicylic acid (PAS) perturbs folate metabolism in <i>M. tuberculosis</i> as a prodrug, which after bioactivation by other enzymes of the folate pathway acts as a <i>MtDHFR</i> inhibitor.	[130] [131]
	2014	Missense mutations residing within the active site coding region of dihydrofolate synthase, one of the PAS activation enzymes, found in clinical isolates of <i>M. tuberculosis</i> were identified as the causative of PAS resistance.	[134]
	2014	Unlike methotrexate its diester derivatives with increased lipophilicity exhibited significant whole-cell potency against <i>M. tuberculosis</i> possibly because of enhanced penetration rate. It is suggested that these derivatives act through the disruption of methyl-transfer mediated by S-adenosylmethionine.	[132]
	2014 2015	Development of 2,4-diamino-triazin derivatives resulted in <i>MtDHFR</i> inhibitors with favorable whole cell activity against <i>Mtb</i> (MIC < 2µM) along with low and moderate cytotoxicity.	[144] [145] [146]
	2015	Minireview on mechanism of PAS action and resistance.	[135]
	2015	Study of a focused library including more than 2000 compounds identified a 2,4-diaminoquinazoline derivative with promising <i>in vivo</i> antitubercular efficiency and low host cell toxicity.	[143]
	2015	Modeling study on <i>MtDHFR</i> proposed selective and potent agents against <i>MtDHFR</i> .	[142]
	2015	<i>In silico</i> screening for <i>MtDHFR</i> inhibitors identified two compounds with the tetrahydro-1,3,5-triazin-2-amine scaffold, which were active against <i>M. bovis</i> BCG (MIC < 5µM).	[147]
	2016	Mutation resulting PAS resistance in <i>M. tuberculosis</i> revealed that gene <i>Rv2671</i> was misannotated. Overexpression of <i>Rv2671</i> protein resulted in bacterial escape of PAS treatment, which observation led to the discovery that this protein is a DHFR.	[136]
<b><i>Candida glabrata</i> <i>Candida albicans</i></b>	1996	Development of 1,3-diaminopyrrolo-quinazolines against <i>C. albicans</i> resulted in compounds with great <i>in vivo</i> and <i>in vitro</i> potency. However these were even more potent against <i>hDHFR</i> and toxic for HCT cell lines.	[148]
	2004	Inconsistencies were found in the case of drugs targeting <i>C. albicans</i> between the effect of those on <i>CaDHFR</i> activity and on parasite growth. Designed compounds were found to be potent but not selective.	[149]
	2008	Based on <i>CgDHFR</i> crystal structure two drugs possessing subnanomolar potency against the enzyme and significantly impairing <i>C. glabrata</i> growth were designed. These were also highly selective <i>in vitro</i> and showed low toxicity against mammalian cells.	[115]
	2009	Structure activity relationship study of propargyl-linked 1,3-diaminopyrimidines targeting <i>CaDHFR</i> .	[150]

		Antifungal activity is still not well correlated with <i>Ca</i> DHFR inhibition. Resulting compounds are toxic to human cells in the concentration effective against <i>C. albicans</i> .	
	2009	Derivatives of the best active 1,3-diaminopyrimidine compounds from Ref [115] were outperformed by the unmodified compounds in terms of activity against <i>Cg</i> DHFR In the crystal structures of <i>Cg</i> DHFR only R-enantiomers of the inhibitors were found in the active center.	[151]
	2011	Structure based study on improving the affinity of moderately potent compounds from Ref [150] against <i>Ca</i> DHFR. Increasing hydrophobicity at certain positions enhanced the extent of the van der Waals contacts.	[152]
	2013	Replacing a phenyl group of the best active compounds from Ref [115] with aromatic or alicyclic heterocycles resulted in derivatives with decreased efficiency of <i>Ca</i> DHFR inhibition and selectivity ratios.	[153]
	2014	Three compounds from a set of novel propargyl-linked 1,3-diaminopyrimidines proved to possess outstanding antifungal activity (MIC<1 µg/mL) and <i>in vivo</i> selectivity.	[154]
	2016	Validation of an <i>in silico</i> inverse docking method for predicting selectivity of <i>Ca</i> DHFR inhibitors.	[155]

475



## 3.2. Bifunctional DHFR-TS

Protozoa encode bifunctional DHFR-TSs, in which the TS domain is fused to the carboxy terminal of the DHFR domain by a junction peptide of varying size. Thus the two enzyme domains do not share a common folate binding site, unlike in the case of bifunctional dCTP deaminase – dUTPase [28]. The fusion of the two proteins facilitates dihydrofolate elimination through metabolic channeling and allows sufficient coordinate control of folate metabolizing enzymes, which might represent a biological advantage of such bifunctional DHFR-TSs [156]. The junction of the two proteins is generally not considered as the source of differences in drug actions, which is rather assigned to the sequence diversity [157,158]. Although this flexible linker does not influence the action of classical antifolates it might be a subject of specific inhibitor design, since it modulates enzyme activity in some specific cases [159,160]. Compounds binding to the dimer interface and acting as allosteric inhibitors of DHFR-TSs are also in the scope of drug design projects [161,162]. Still, the main approach targeting these bifunctional DHFR-TS enzymes is the development of specific DHFR inhibitors (Table 6).

### 3.2.1. Plasmodium species

Fast adaptation of *Plasmodium falciparum* DHFR-TS by specific mutations in the active site triggers continuous drug development programs against the emerging mutant enzymes.

In most cases mutations which led to drug-resistance were associated with steric exclusion of the conformationally constrained inhibitors. Based on this observation compounds with increased flexibility have been developed against *Pf*DHFR-TS to overcome fast adaptation of the parasite [163]. Combination of this principle and structure based drug design aided by crystal structures of substrates and inhibitors in complex with wild-type and quadruple mutant *Pf*DHFR-TS resulted in compounds which inhibit both the wild type and the mutant protozoan enzyme [163–165]. It has also been shown that one of the derivatives, namely P218, displays *in vivo* activity against wild-type and pyrimethamine-resistant malarias [163]. Since the pre-clinical safety studies have been completed for the drug candidate P218, it may proceed to first in-human tests<sup>2</sup>, meanwhile a recent molecular modeling analysis might facilitate the synthesis of P218 derivatives with enhanced performance [166]. In parallel with

<sup>2</sup> MMV (Medicines for Malaria Venture) Research and Development

these studies new scaffolds for inhibitor design against *Pf*DHFR-TS were also studied to different extents [166–170].

Besides mutations in *Pf*DHFR–TS, it has been shown that gene amplification of GTP-cyclohydrolase, the first enzyme in the folate synthesis pathway of the parasite, is strongly associated with antifolate drug resistance, revealing this enzyme as a potential new target to be considered for antimalarial drug design [171].

### 3.2.2. Leishmania

While the *Plasmodium* enzyme is the target of pyrimethamine, one of the few clinically active anti-malarial agents, this drug despite the high similarity of protozoan TS-DHFRs is ineffective to treat leishmaniasis. This difference in pyrimethamine inhibition is associated with the observation that this drug acts on the DHFR domain which – unlike the highly conserved TS domain – is more variable between species, albeit these differences are much smaller, than those between the human and protozoan enzymes. Other common antimicrobial DHFR inhibitors such as cycloguanil and trimethoprim were also not effective against *Leishmania*.

In *Plasmodium* point mutations in the DHFR gene are the source of pyrimethamine resistance, while *Leishmania* acts against antifolates by amplification of the gene encoding DHFR [156]. As such it is expected that *Leishmania* is less capable to develop resistance-inducing mutations.

Some quantitative structure activity relationship schemes of some antifolates against *L. major* have already been established in early studies, however, these were abandoned, possibly because of insufficient selectivity profile of the compounds [172,173]. Later, during the development of *Trypanosomal* DHFR-TS inhibitors some moderately active inhibitors of *L. infantum* and *L. donovani* have been reported [122,174]. The structure of *Lm*DHFR-TS has been solved, albeit the crystallographic data is not available in Protein Data Bank [158]. Recent studies report only *in silico* testing of limited set of compounds against homology models of *L. donovani chagasi* and *L. major* [158,175,176]. However recently promising preclinical development candidates against *L. donovani* exhibited moderate inhibition of *Ld*DHFR-TS and inhibitory effects on promastigotes and amastigotes by triggering their apoptotic cascade [177].

### 3.2.3. Trypanosomas

To overcome drug resistance of *T. cruzi*, *T. brucei* and *L. infantum* series of compounds were tested against DHFR-TS of these parasites, which resulted in good activity and selectivity leads against the protozoan enzymes [174]. Pyrimidine analogues including trimetrexate, a DHFR inhibitor used in pneumocystis pneumonia therapy, were active *in vitro* but exhibited only limited activity *in vivo* [178,179]. Diaminoquinazoline derivatives showed a more promising *in vivo* profile [122,180] and hence these are in the focus of extensive structure based drug design [181–185]. Based on these studies potent inhibitors against Trypanosomal DHFR-TSs have already been developed, however overcoming selectivity problems is still a challenge.

#### 3.2.4. *Toxoplasma gondii*

Comprehensive research has been performed to find selective inhibitors against *Toxoplasma gondii* DHFR-TS as a validated drug target [186]. Since *Toxoplasma* cannot salvage dTTP from an extracellular source, indirect inactivation of thymidylate synthase *via* DHFR inhibition is lethal to the parasite [187]. The design of *Tg*DHFR-TS inhibitors has largely relied on *in vitro* screening and homology modeling [114,188–190], where fine-tuning of human DHFR inhibitors against the *T. gondii* enzyme resulted in some potent and selective drug candidates [190]. Future studies will be directed towards improving the best active tricyclic pyrimido[4,5-b]indole scaffold based on the comparison of the recently determined crystal structures of *Tg*DHFR-TS with its human counterpart [190,191].

Exploiting this structural information research projects aiming to identify allosteric inhibitors targeting the TS-TS dimer interface of the *Tg*DHFR-TS have also been launched [190,191]. The moderately potent compounds reported from these studies serve as proof-of-concept and may lead to design and optimization of novel class of potent and selective inhibitors to treat toxoplasmosis [161,162].

#### 3.2.5. *Cryptosporidium hominis*

The crystal structure of *Cryptosporidium hominis* DHFR-TS was determined in the early 2000s [192,193], enabling structure based drug design of selective inhibitors of the enzyme. Derivatization of trimethoprim by applying a propargyl linker resulted in novel series of classical antifolates with nanomolar inhibitory constants ( $K_i$ ) against *Ch*DHFR-TS [114,194] and remarkable *in vivo* activity [40,195]. However, difficulties were observed in transport of the best potent compound through the vacuolar membranes of the parasite [40], which could

be overcome by loading the inhibitor into PLGA nanoparticles fused to *Cryptosporidium* specific antibody [196]. Future development strategies will focus on improving the selectivity against the human enzyme without compromising the activity against *Ch*DHFR-TS by applying computer-aided design [40].

It has been shown that mutations in the linker region, especially inside the crossover helix of the *C. hominis* DHFR, impair the catalytic rate of the enzyme, which implies that the linker is necessary for optimal dihydrofolate reductase activity. Initiated by this finding, studies applying virtual screening and structure based design independently resulted in mid-micromolar allosteric inhibitors [159,160]. Subsequent synthetic development of these proof-of-concept compounds to possess higher affinity to the identified surface cleft will presumably eventuate in more potent, novel inhibitors against *Ch*DHFR-TS.

579 **Table 6.** Recent results on the inhibition of bifunctional dihydrofolate reductase – thymidylate  
580 synthases

Organism	Year	Summary	Ref.
<i>Plasmodium falciparum</i>	1997	Identifying mutations responsible for drug resistance of <i>Pf</i> DHFR-TS.	[197]
	2003	Crystal structure of wild-type and mutant <i>Pf</i> DHFR-TS enzymes serves as templates for designing novel drugs against resistant-mutant parasites. Junction region might be a target for selective inhibitors interfering with interdomain interactions.	[164]
	2004	Report on low nanomolar level inhibitors targeting the mutant enzymes with good antimalarial activities against resistant <i>P. falciparum</i> parasites and low or moderate cytotoxicity candidates for novel antimalarials.	[198]
	2009	Novel inhibitors with guanidine scaffold were found to be active against wild-type and mutant <i>Pf</i> DHFR-TS enzymes. Co-crystal of novel inhibitors with a drug-resistant mutant <i>Pf</i> DHFR-TS.	[199]
	2010	Drug candidate, QN254 however showed relative <i>in vitro</i> selectivity towards the Plasmodium DHFR enzyme possesses inadequate therapeutic index tested in rats. Compound relinquished.	[200]
	2012	Identification of selective and potent inhibitors of wild-type and mutant <i>Pf</i> DHFR-TS enzymes, with good metabolic properties. Compound P218 was denominated as a pre-clinical candidate.	[163]
	2013	4,6-diaryl-2-aminopyrimidine derivatives proved to be promising leads for inhibitor design against <i>Pf</i> DHFR-TS.	[167]
	2014	Compounds from <i>Brucea mollis</i> Wall. ex kurz were <i>in silico</i> checked against wild type and mutant <i>Pf</i> DHFR-TS. Inhibitors with better binding affinity than pyrimethamine were identified.	[168]
	2014	Molecular dynamics simulation of interactions between rigid and flexible antifolates of wild-type and pyrimethamine-resistant mutant of <i>Pf</i> DHFR-TS. Description of key inhibitor binding residues.	[169]
	2014	Molecular dynamics analysis of inhibitor P218 binding to wild-type and mutant <i>Pf</i> DHFR-TS.	[166]
	2014	Guanyltiourea derivatives with IC <sub>50</sub> value of 100 µM and 400 nM were developed against <i>Pf</i> DHFR-TS.	[170]
<i>Plasmodium ovale</i>	2012	Antifolate drugs showed similar kinetic and sensitivity profiles with <i>Po</i> DHFR-TS as compared to those of the <i>P. falciparum</i> and <i>P. vivax</i> enzymes.	[201]
<i>Plasmodium vivax</i>	2001	Transgenic Plasmodium lines expressing <i>Pv</i> DHFR-TS for screening anti- <i>P. vivax</i> compounds targeting this enzyme.	[202]
	2006	Testing compounds on a <i>Pv</i> DHFR-TS-dependent bacterial strain, revealed that inhibitors of this enzyme are similar to those of <i>Pf</i> DHFR-TS. Adequate correlation was found between the <i>in vitro</i> enzyme inhibition constants and the IC <sub>50</sub> values.	[203]
<i>Leishmania major</i>	2012	<i>In silico</i> modelling study of <i>Lm</i> DHFR-TS and virtual screening for its inhibitors.	[176]
	2012	Promising preclinical development candidates with moderate inhibition of <i>Ld</i> DHFR-TS showed inhibitory effects on <i>L. donovani</i> promastigotes	[177]

		and amastigotes by triggering of the apoptotic cascade.	
<b><i>Leishmania donovani</i></b>	1999	Series of compounds were tested against <i>T. cruzi</i> , <i>T. brucei</i> and <i>L. infantum</i> DHFR-TS. Leads for drug development with good activity and selectivity against the protozoan enzymes were identified.	[174]
	2010	Modeling the structure of <i>Leishmania donovani chagasi</i> DHFR-TS to aid future drug design programs.	[175]
<b><i>Trypanosoma brucei, cruzi</i></b>	2002	2,4-diaminopyrimidines are potent inhibitors of the <i>Trypanosomal</i> DHFR-TS enzymes <i>in vitro</i> , but show only limited activity <i>in vivo</i> .	[178] [179]
	2005	The quinazoline derivative antifolate, trimetrexate is proven to a potent but not selective inhibitor of <i>Tc</i> DHFR-TS. Outset of drug development is the improvement of the selectivity of this compound.	[180]
	2005	2,4-diaminoquinazoline-based compounds inhibited <i>Tc</i> DHFR-TS and <i>Tb</i> DHFR-TS and have <i>in vivo</i> activity in a rodent model of Chagas disease, but lack activity against the <i>L. donovani</i> .	[122]
	2008	First crystal structures of apo and inhibitor bound <i>Tc</i> DHFR. 3D-QSAR analysis of inhibitors of <i>Tc</i> DHFR activity. Identification of several highly potent inhibitors of <i>Tc</i> DHFR from libraries of antifolate compounds.	[181] [182] [183]
	2010	Introducing chemical modifications on trimetrexate did not resulted in additional favorable contacts with <i>Tc</i> DHFR nor disfavor <i>h</i> TS binding.	[184]
	2011	First Crystal structure of DHFR domain of <i>Tb</i> DHFR with NADPH and inhibitors. <i>Tb</i> DHFR is similar to pyrimethamine resistant mutant <i>Pf</i> DHFRs. During inhibition design steric hindrance of Thr86 clash should be considered	[185]
<b><i>Toxoplasma gondii</i></b>	2002	<i>De novo</i> pyrimidine biosynthesis is essential for virulence of <i>T. gondii</i> .	[186]
	2007	Rational lead design based on homology model of <i>Tg</i> DHFR-TS and crystal structure of <i>Ch</i> DHFR-TS. Change of the one carbon linker in trimethoprim with a longer but rigid propargyl linker to access hydrophobic pocket of DHFR active site resulted in compounds displaying high potency and selectivity against <i>Tg</i> DHFR-TS and <i>Ch</i> DHFR-TS.	[114]
	2008	Among potent compounds constructed during the development of inhibitors against <i>h</i> TS, a class of derivatives was proven to be only marginally active on the human target. These however showed high potency and selectivity against <i>Tg</i> DHFR-TS.	[188]
	2013	Comparative docking to the homology model of <i>Tg</i> DHFR-TS applying different softwares for screening the same drug library resulted in several potential inhibitors of this enzyme.	[189]
	2013	First crystal structure of <i>Tg</i> DHFR-TS aiding structure based inhibitor design.	[191]
	2013	Compounds with single-digit nanomolar $K_i$ for <i>Tg</i> DHFR-TS, with 28- and 122-fold selectivity over human TS ( <i>h</i> TS) were synthesized on the basis of the potent bicyclic <i>h</i> TS inhibitor nolatrexed.	[190]

	2013	$\beta$ -strand mimicking peptides that target dimer interface of <i>Tg</i> DHFR-TS inhibit enzymatic activity in a species-specific manner. Non-conserved residues in the linker between TS and DHFR play a key role in domain–domain communication and in peptide interaction.	[162]
	2013	<i>In silico</i> screening for allosteric inhibitors at the interface between the two TS domains. Identified compounds showed moderate inhibition of <i>Tg</i> DHFR-TS but no selectivity against <i>h</i> TS.	[161]
<i>Cryptosporidium hominis</i>	2003, 2005	Crystal structures of <i>Ch</i> DHFR-TS revealing protein-ligand interactions provide template for structure-based drug design against <i>Ch</i> DHFR-TS.	[192] [193]
	2007	Highly efficient inhibitors of <i>Ch</i> DHFR-TS (cf. at <i>T. gondii</i> ).	[114]
	2008	Structure-based inhibitor development resulted in enhanced affinity compounds from Ref. [114] against <i>Ch</i> DHFR-TS, without compromising selectivity.	[194]
	2009	<i>Ch</i> DHFR-TS crossover helix is indispensable for adequate enzyme activity since mutations in this region resulted in a drastic reduction of catalytic rate.	[204]
	2008	Novel non-active site inhibitors with mid-micromolar potency against of <i>Ch</i> DHFR-TS were identified by a virtual screening revealed inhibitory potential of an allosteric pocket of this enzyme.	[159]
	2013	Small molecule compound binding at the species-specific helical protein interaction surface could result in catalytic inhibition and enzyme destabilization.	[160]
	2013	A novel series of classical antifolates, were proven to be potent inhibitors of <i>Ch</i> DHFR-TS. Inhibitor bound crystal structure reveals key structural differences between <i>Ch</i> DHFR-TS and <i>h</i> TS and aids the design of parasite specific agents.	[195]
	2014	Identification of a potent inhibitor of <i>Ch</i> DHFR-TS with anti-cryptosporidial activity in cell culture. Difficulties in delivery of the potent compounds through the vacuolar membranes of the parasite were observed.	[40]
	2015	PLGA nanoparticles fused to <i>Cryptosporidium</i> specific antibodies loaded with a potent inhibitor of <i>Ch</i> DHFR-TS specifically targeted the parasite. This formulation reduced the level of parasites by 200-fold in cell culture as compared to the 4.4-fold decrease upon normal inhibitor addition.	[196]

581

582

## 4. Other promising targets

### 4.1. Serine hydroxymethyltransferase inhibitors

Since serine hydroxymethyltransferase (SHMT) plays a key role in the dTMP synthesis (Figure 1) it is a highly relevant target for antiparasite drugs. Still, inhibitor development was only reported in the case of *Plasmodium* SHMT, which enzyme was validated as an antimalarial platform [205–209]. Differences in the structure of the ligand binding pockets of human and *Plasmodium* SHMTs have been exploited during the design of species-specific inhibitors against the protozoal enzyme [209]. The excessive efforts for developing *Pf*SHMT inhibitors resulted in leads with high selectivity margin relative to mammalian cell lines and active also against the tested multidrug resistant *Plasmodium falciparum* strains [210,211]. However further studies are required to enhance the low metabolic stability of the best active *Pf*SHMT inhibitors.

Characterization of *Mycobacterial* and *Trypanosomal* SHMTs have been performed, as a first step of drug design against these enzymes [212–217]. It has been shown that unlike eukaryotic SHMTs including those of other trypanosomatids, *T. cruzi* SHMT does not oligomerize in solution [217]. While the genome of *M. tuberculosis* encodes two different dimeric SHMTs, which also differ from the tetrameric mammalian enzymes [212,213]. In most SHMTs except, among others, the *Mycobacterial* enzymes, a strictly conserved lysine forms covalent bond with the cofactor pyridoxal phosphate. *Mycobacterial* SHMTs uniquely display significant changes in the conserved threonine-rich octapeptide sequence near this active site lysine residue [212,213], which might explain the slightly distinct catalytic properties of these enzymes compared to other SHMTs.

These marked differences of *T. cruzi* and *Mycobacterial* SHMTs to other isoenzymes might facilitate specific drug development against these targets, whereas the high similarity between *Leishmanial* and human SHMTs renders the design of specific inhibitors of *Ld*SHMT challenging [214,215].



## 4.2. Thymidine kinase inhibitors

It has been proven that the pyrimidine nucleotide salvage is indispensable *in vivo*, by knocking out thymidine kinase (TK) the key enzyme of the pathway in mice [218]. Thus TK is also a potential objective of antiparasite drug development [218–222]. Such as in the case of *Cryptosporidium parvum*, thymidine kinase is found to be an effective target in anti-cryptosporidial therapy [222], since the treatment of the bacteria with fluorinated pyrimidine derivatives processed by the pro-drug activator CpTK resulted in inhibition of parasite growth in an *in vitro* model of infection and was found effective in a mouse model, as well.

*Leishmania major* TK (*LmTK*) knockout mutants also showed lower proliferation rates, morphological defects and were found to be less infective [219]. However, a recent crystallographic study revealed that the active site of *LmTK* is analogous to that of the human enzyme [220]. This is also demonstrated by the highly similar kinetic parameters associated with the binding of substrates and inhibitors, depicting the design of selective *LmTK*-specific inhibitors even more elusive.

While *T. brucei* thymidine kinase (*TbTK*), which was shown to be a pseudo-dimer of covalently linked tandem repeat of monomers, has broader substrate specificity than the human enzyme and is therefore a more feasible drug target [221].

Thymidine kinase inhibition is not applicable against several parasites including *Pseudomonas aeruginosa*, *Helicobacter pylori*, *Toxoplasma gondii* and *Mycobacteria* which do not encode this enzyme [11,187], although the lack of thymine nucleotide salvage sensitizes these organisms for inhibitors of the *de novo* synthesis pathway.

### 4.3. Thymidylate kinase inhibitors

As TMPK catalyses the formation of dTDP from dTMP, it is essentially important in the dTTP synthesis pathway for DNA synthesis, and also as an antiparasite drug target [223]. Inhibition of *Staphylococcus aureus* TMPK has resulted in *in vivo* anti-staphylococcal efficacy in mouse model and the inhibitor molecule was proven to be selective against the human enzyme [224,225]. Compounds with nanomolar inhibition potency against *Pseudomonas aeruginosa* thymidylate kinase have also been developed, however those were ineffective against the bacteria possibly due to poor penetration of the drug through the complex cell membrane [226]. Investigation of thymidine monophosphate analogs against *Mt*TMPK resulted only in very weak inhibitors [227,228], whereas compounds with thymidine core and their acyclic bioisosteres were found to be more promising lead candidates with micromolar or lower inhibitory constants ( $K_i$ ) and favorable selectivity [229–231]. Recently three novel compound series were also tested against *Mt*TMPK [232]. The development of 1,6-naphthyridinone compounds has not led to high potency *Mt*TMPK inhibitors, thus the focus was shifted to cyanopyridones. These showed single digit nanomolar *in vitro* activity, but were ineffective in cellular assays. The third series containing sulfoxide or sulfone substituents showed anti-mycobacterial activity at low micromolar concentrations. The correlation analysis of *in vitro* and *in vivo* activities revealed that the observed antimycobacterial effect is not exclusively originates from *Mt*TMPK inhibition, hence further target validation is required in case of these compounds. The same holds for inhibitors developed against the *Pf*TMPK, which exhibit promising antimalarial activity and selectivity between *P. falciparum* and human enzymes, but the mechanism of *in vivo* action is yet equivocal [233]. To best of our knowledge, no report is yet available on *Leishmanial* TMPKs, also in the case of *B. anthracis* TMPK only a preliminary study has been reported to date [234].

## 5. New waves: proteinaceous inhibition of dUTPase and UNG

Recently a Staphylococcal protein (Stl) has been identified as a competitive inhibitor of a phage related dUTPase with nanomolar inhibitory constant [235–237]. It has also been shown that the inhibition is independent from the phage specific insert and Stl binds and inhibits *Mycobacterial* dUTPases *in vitro* and *in vivo* [238,239]. These developments shed light on the possibility of using protein inhibitors to target enzymes in the thymidylate biosynthesis pathway. Proteinaceous inhibition and the use of proteins as drugs have several advantages and disadvantages, as well. Among the positive factors, it should be mentioned first of all, that macromolecular inhibition may offer unprecedented specificity, and can also be tailored using site-specific mutations to target dUTPases from different species. However, the use of proteins as drugs may imply many technical difficulties, among which the question how we can achieve an effective concentration of the macromolecular inhibitor in the vicinity of the target protein remains to be elusive. Still, despite all technical difficulties, macromolecular drugs are up coming and it can be expected that such approaches will prove to be successful in the next few years.

Another proteinaceous inhibitor within the DNA damage and repair pathways is the uracil-DNA glycosylase inhibitor Ugi. A recent study suggests that depletion of the uracil DNA glycosylase (UNG) sensitizes tumor cells to FdUrd, because of activation more error prone DNA repair mechanisms against the incorporated 5F-uracil [236]. We propose that the potential significance of a proteinaceous inhibitor against UNG can be tested in pathogens, as well. In this regard a pioneering study on the recently discovered Ugi protein from *Staphylococcus aureus* attempts to modulate the inhibitor ability of this protein against human herpesvirus UDG [240,241]. Based on the promising results of these first experiments, the Ugi inhibitor may serve as a new type of drug candidate molecule.

## Conclusions

We have reviewed the current state of using drugs against thymidylate biosynthesis to fight pathogenic microorganisms. Some major general aspects may be emphasized in these efforts. Since in many cases, e.g. with dUTPases and thymidylate synthases, the target pathogen enzyme has a closely-related human homologue as well, the problem of selectivity has to be addressed. This can be approached in two ways: on the one hand, the designed drug candidate

may possess chemical moieties that enhance selectivity [13], whereas on the other hand, the targeted enzyme surface needs to include species-specific segments [15].

In more convenient scenarios, the target enzyme in the pathogenic microorganisms possesses either somewhat altered three-dimensional structure or completely different protein fold, allowing a more straightforward approach for pathogen species-specific drug design. Examples in these cases include e.g the Plasmodium dUTPase where one protein segment shows a distinct conformation as compared to human dUTPase, as well as the dUTPases from Trypanosomes and Leishmania species, which are representatives of the all- $\alpha$  dimeric dUTPase family possessing also an altered mechanism of action as compared to the more general all- $\beta$  trimeric dUTPases. In the family of thymidylate synthases, some pathogens, like *Mycobacterium tuberculosis* and *Helicobacter pylori*, luckily encode this enzymatic activity in a protein (nick-named as ThyX) that is fully divergent from its human counterpart.

Further, to overcome the mechanisms of development of resistance, the novel drug candidates need to possess new mechanisms of action. It is also a promising concept to apply combination therapies by simultaneous application of drug candidates targeting different enzymes. Finally, during the fine-tuning of drug-like compounds, the key properties that are significant for drug action (eg solubility, penetration properties, specificity, toxicity) should be optimized in parallel to each other.

## Acknowledgements

Authors thank for the support of Hungarian Scientific Research Fund OTKA [NK 84008, K109486]; Baross Program of the New Hungary Development Plan [3DSTRUCT, OMFB-00266/2010 REG-KM- 09-1-2009-0050]; Hungarian Academy of Sciences ([TTK IF-28/2012]; MedinProt program); the ICGEB Research Grant to BGV (CRP/HUN14-01) and the European Commission FP7 Biostruct-X project [contract No. 283570]. Funding for open access charge: Hungarian Academy of Sciences.

## References

- [1] H.I.M. Boshoff, M.B. Reed, C.E. Barry, V. Mizrahi, DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in *Mycobacterium tuberculosis*, *Cell*, 113 (2003) 183–193.
- [2] A.C. Anderson, D.L. Wright, Antifolate agents: a patent review (2006-2010), *Expert Opin. Ther. Pat.*, 21 (2011) 1293–1308.
- [3] A.C. Anderson, D.L. Wright, Antifolate agents: a patent review (2010-2013), *Expert Opin. Ther. Pat.*, 24 (2014) 687–697.
- [4] B.G. Vértessy, J. Tóth, Keeping uracil out of DNA: physiological role, structure and catalytic mechanism of dUTPases, *Acc. Chem. Res.*, 42 (2009) 97–106.
- [5] G.N. Nagy, I. Leveles, B.G. Vértessy, Preventive DNA repair by sanitizing the cellular (deoxy)nucleoside triphosphate pool, *FEBS J.*, 281 (2014) 4207–23.
- [6] V.M. Castillo-Acosta, A.M. Estévez, A.E. Vidal, L.M. Ruiz-Perez, D. González-Pacanowska, Depletion of dimeric all- $\alpha$  dUTPase induces DNA strand breaks and impairs cell cycle progression in *Trypanosoma brucei*, *Int. J. Biochem. Cell Biol.*, 40 (2008) 2901–13.
- [7] G.R. Hemsworth, O. V Moroz, M.J. Fogg, B. Scott, C. Bosch-Navarrete, D. González-Pacanowska, K.S. Wilson, The crystal structure of the *Leishmania major* deoxyuridine triphosphate nucleotidohydrolase in complex with nucleotide analogues, dUMP, and deoxyuridine, *J. Biol. Chem.*, 286 (2011) 16470–81.
- [8] M. Harkiolaki, E.J. Dodson, V. Bernier-Villamor, J.P. Turkenburg, D. González-Pacanowska, K.S. Wilson, The crystal structure of *Trypanosoma cruzi* dUTPase reveals a novel dUTP/dUDP binding fold, *Structure*, 12 (2004) 41–53.
- [9] O. V Moroz, M. Harkiolaki, M.Y. Galperin, A.A. Vagin, D. González-Pacanowska, K.S. Wilson, The crystal structure of a complex of *Campylobacter jejuni* dUTPase with substrate analogue sheds light on the mechanism and suggests the “basic module” for dimeric d(C/U)TPases, *J. Mol. Biol.*, 342 (2004) 1583–97.
- [10] O.K. Mc Carthy, A. Schipani, A.M. Buendía, L.M. Ruiz-Perez, M. Kaiser, R. Brun, D.G. Pacanowska, I.H. Gilbert, Design, synthesis and evaluation of novel uracil amino acid conjugates for the inhibition of *Trypanosoma cruzi* dUTPase, *Bioorg. Med. Chem. Lett.*, 16 (2006) 3809–3812.
- [11] H. Saito, H. Tomioka, Thymidine kinase of bacteria: activity of the enzyme in actinomycetes and related organisms, *J. Gen. Microbiol.*, 130 (1984) 1863–70.
- [12] S. Chan, B. Segelke, T. Lakin, H. Krupka, U.S. Cho, M.-Y. Kim, M. So, C.-Y. Kim, C.M. Naranjo, Y.C. Rogers, M.S. Park, G.S. Waldo, I. Pashkov, D. Cascio, J.L. Perry, M.R. Sawaya, Crystal structure of the *Mycobacterium tuberculosis* dUTPase: insights into the catalytic mechanism, *J. Mol. Biol.*, 341 (2004) 503–17.
- [13] J.L. Whittingham, I. Leal, C. Nguyen, G. Kasinathan, E. Bell, A.F. Jones, C. Berry, A. Benito, J.P. Turkenburg, E.J. Dodson, L.M. Ruiz Perez, A.J. Wilkinson, N.G. Johansson, R. Brun, I.H. Gilbert, D. Gonzalez Pacanowska, K.S. Wilson, dUTPase as a

- 753 platform for antimalarial drug design: structural basis for the selectivity of a class of  
754 nucleoside inhibitors, *Structure*, 13 (2005) 329–38.
- 755 [14] B. Varga, O. Barabás, E. Takács, N. Nagy, P. Nagy, B.G. Vértessy, Active site of  
756 mycobacterial dUTPase: structural characteristics and a built-in sensor, *Biochem.*  
757 *Biophys. Res. Commun.*, 373 (2008) 8–13.
- 758 [15] K. Horváti, B. Bacsá, N. Szabó, K. Fodor, G. Balka, M. Rusvai, É. Kiss, G. Mező, V.  
759 Grolmusz, B. Vértessy, F. Hudecz, S. Bősze, Antimycobacterial activity of peptide  
760 conjugate of pyridopyrimidine derivative against *Mycobacterium tuberculosis* in a  
761 series of in vitro and in vivo models, *Tuberculosis*, 95 (2015) 207–211.
- 762 [16] J.J. Irwin, B.K. Shoichet, ZINC – A Free Database of Commercially Available  
763 Compounds for Virtual Screening ZINC - A Free Database of Commercially Available  
764 Compounds for Virtual Screening, *J. Chem. Inf. Model*, 45 (2005) 177–182.
- 765 [17] I. Pecsí, R. Hirmondo, A.C. Brown, A. Lopata, T. Parish, B.G. Vértessy, J. Tóth, The  
766 dUTPase enzyme is essential in *Mycobacterium smegmatis*, *PLoS One*, 7 (2012)  
767 e37461.
- 768 [18] G.J. Crowther, A.J. Napuli, J.H. Gilligan, K. Gagaring, R. Borboa, C. Francek, Z.  
769 Chen, E.F. Dagostino, J.B. Stockmyer, Y. Wang, P.P. Rodenbough, L.J. Castaneda,  
770 D.J. Leibly, J. Bhandari, M.H. Gelb, A. Brinker, I.H. Engels, J. Taylor, A.K.  
771 Chatterjee, P. Fantauzzi, et al., Identification of inhibitors for putative malaria drug  
772 targets among novel antimalarial compounds, *Mol. Biochem. Parasitol.*, 175 (2011)  
773 21–29.
- 774 [19] E. Recio, A. Musso-Buendía, A.E. Vidal, G.F. Ruda, G. Kasinathan, C. Nguyen, L.M.  
775 Ruiz-Pérez, I.H. Gilbert, D. González-Pacanowska, Site-directed mutagenesis provides  
776 insights into the selective binding of trityl derivatives to *Plasmodium falciparum*  
777 dUTPase, *Eur. J. Med. Chem.*, 46 (2011) 3309–14.
- 778 [20] B. Baragaña, O. McCarthy, P. Sánchez, C. Bosch-Navarrete, M. Kaiser, R. Brun, J.L.  
779 Whittingham, S.M. Roberts, X.X. Zhou, K.S. Wilson, N.G. Johansson, D. González-  
780 Pacanowska, I.H. Gilbert,  $\beta$ -Branched acyclic nucleoside analogues as inhibitors of  
781 *Plasmodium falciparum* dUTPase, *Bioorganic Med. Chem.*, 19 (2011) 2378–2391.
- 782 [21] R. de Araújo Santos, C. Braz, J. Ghasemi, R. Safavi-Sohi, E. Barbosa, Mixed 2D–3D-  
783 LQTA-QSAR study of a series of *Plasmodium falciparum* dUTPase inhibitors, *Med.*  
784 *Chem. Res.*, 24 (2015) 1098–1111.
- 785 [22] A. Camacho, R. Arrebola, J. Pena-Díaz, L.M. Ruiz-Perez, D. Gonzalez-Pacanowska,  
786 Description of a novel eukaryotic deoxyuridine 5'-triphosphate nucleotidohydrolase in  
787 *Leishmania major*, *Biochem J*, 325 (1997) 441–447.
- 788 [23] A. Camacho, F. Hidalgo-Zarco, V. Bernier-Villamor, L.M. Ruiz-Pérez, D. González-  
789 Pacanowska, Properties of *Leishmania major* dUTP nucleotidohydrolase, a distinct  
790 nucleotide-hydrolysing enzyme in kinetoplastids, *Biochem. J.*, 346 Pt 1 (2000) 163–  
791 168.
- 792 [24] F. Hidalgo-Zarco, A.G. Camacho, V. Bernier-Villamor, J. Nord, L.M. Ruiz-Pérez, D.  
793 González-Pacanowska, Kinetic properties and inhibition of the dimeric dUTPase-  
794 dUDPase from *Leishmania major*, *Protein Sci.*, 10 (2001) 1426–1433.

- 795 [25] V.M. Castillo-Acosta, F. Aguilar-Pereyra, D. García-Caballero, A.E. Vidal, L.M. Ruiz-  
796 Pérez, D. González-Pacanowska, Pyrimidine requirements in deoxyuridine  
797 triphosphate nucleotidohydrolase deficient *Trypanosoma brucei* mutants, *Mol.*  
798 *Biochem. Parasitol.*, 187 (2013) 9–13.
- 799 [26] G.R. Hemsworth, D. González-Pacanowska, K.S. Wilson, On the catalytic mechanism  
800 of dimeric dUTPases, *Biochem. J.*, 456 (2013) 81–8.
- 801 [27] J.A. Musso-Buendía, A.E. Vidal, G. Kasinathan, C. Nguyen, J. Carrero-Lérida, L.M.  
802 Ruiz-Pérez, K. Wilson, N.G. Johansson, I.H. Gilbert, D. González-Pacanowska,  
803 Kinetic properties and inhibition of the dimeric dUTPase-dUDPase from  
804 *Campylobacter jejuni*, *J. Enzyme Inhib. Med. Chem.*, 24 (2009) 111–116.
- 805 [28] S.S. Helt, M. Thymark, P. Harris, C. Aagaard, J. Dietrich, S. Larsen, M. Willemoes,  
806 Mechanism of dTTP inhibition of the bifunctional dCTP deaminase:dUTPase encoded  
807 by *Mycobacterium tuberculosis*, *J. Mol. Biol.*, 376 (2008) 554–69.
- 808 [29] T.C. Ramalho, M.S. Caetano, D. Josa, G.P. Luz, E.A. Freitas, E.F.F. da Cunha,  
809 Molecular modeling of *Mycobacterium tuberculosis* dUTPase: docking and catalytic  
810 mechanism studies, *J. Biomol. Struct. Dyn.*, 28 (2011) 907–17.
- 811 [30] R. Hirmondo, A. Lopata, É. Böttger, B.G. Vertessy, J. Tóth, Differential control of  
812 dNTP biosynthesis and genome integrity maintenance by dUTPases, *Sci. Rep.*, (2016)  
813 under review.
- 814 [31] C. Nguyen, G. Kasinathan, I. Leal-Cortijo, A. Musso-Buendia, M. Kaiser, R. Brun,  
815 L.M. Ruiz-Pérez, N.G. Johansson, D. González-Pacanowska, I.H. Gilbert,  
816 Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target,  
817 *J. Med. Chem.*, 48 (2005) 5942–5954.
- 818 [32] C. Nguyen, G.F. Ruda, A. Schipani, G. Kasinathan, I. Leal, A. Musso-Buendia, M.  
819 Kaiser, R. Brun, L.M. Ruiz-Perez, B.-L. Sahlberg, N.G. Johansson, D. Gonzalez-  
820 Pacanowska, I.H. Gilbert, Acyclic Nucleoside Analogues as Inhibitors of *Plasmodium*  
821 *falciparum* dUTPase, *J. Med. Chem.*, 49 (2006) 4183–4195.
- 822 [33] I. Quesada-Soriano, J.A. Musso-Buendia, R. Tellez-Sanz, L.M. Ruiz-pérez, C. Barón,  
823 D. González-Pacanowska, L. García-Fuentes, *Plasmodium falciparum* dUTPase:  
824 studies on protein stability and binding of deoxyuridine derivatives, *Biochim. Biophys.*  
825 *Acta*, 1774 (2007) 936–45.
- 826 [34] O. McCarthy, A. Musso-Buendia, M. Kaiser, R. Brun, L.M. Ruiz-Perez, N.G.  
827 Johansson, D.G. Pacanowska, I.H. Gilbert, Design, synthesis and evaluation of novel  
828 uracil acetamide derivatives as potential inhibitors of *Plasmodium falciparum* dUTP  
829 nucleotidohydrolase, *Eur. J. Med. Chem.*, 44 (2009) 678–688.
- 830 [35] L. García-fuentes, A. Vargas-berenguel, D. Gonz, I. Quesada-Soriano, J.M. Casas-  
831 Solvas, E. Recio, L.M. Ruiz-Pérez, D. González-Pacanowska, A. Vargas-berenguel, D.  
832 González-Pacanowska, L. García-fuentes, D. Gonz, A. Vargas-berenguel, D. Gonz, I.  
833 Quesada-Soriano, J.M. Casas-Solvas, E. Recio, L.M. Ruiz-Pérez, D. González-  
834 Pacanowska, A. Vargas-berenguel, et al., Kinetic properties and specificity of trimeric  
835 *Plasmodium falciparum* and human dUTPases, *Biochimie*, 92 (2010) 178–86.
- 836 [36] G.F. Ruda, C. Nguyen, P. Ziemkowski, K. Felczak, G. Kasinathan, A. Musso-Buendia,

- 837 C. Sund, X.X. Zhou, M. Kaiser, L.M. Ruiz-Pérez, R. Brun, T. Kulikowski, N.G.  
838 Johansson, D. González-Pacanowska, I.H. Gilbert, Modified 5'-trityl nucleosides as  
839 inhibitors of Plasmodium falciparum dUTPase, ChemMedChem, 6 (2011) 309–20.
- 840 [37] S.E. Hampton, B. Baragaña, A. Schipani, C. Bosch-Navarrete, J.A. Musso-Buendía, E.  
841 Recio, M. Kaiser, J.L. Whittingham, S.M. Roberts, M. Shevtsov, J. Brannigan, P.  
842 Kahnberg, R. Brun, K.S. Wilson, D. González-Pacanowska, N.G. Johansson, I.H.  
843 Gilbert, Design, Synthesis, and Evaluation of 5'-Diphenyl Nucleoside Analogues as  
844 Inhibitors of the Plasmodium falciparum dUTPase, ChemMedChem, 6 (2011) 1816–  
845 1831.
- 846 [38] S.E. Hampton, A. Schipani, C. Bosch-Navarrete, E. Recio, M. Kaiser, P. Kahnberg, D.  
847 González-Pacanowska, N.G. Johansson, I.H. Gilbert, Investigation of acyclic uridine  
848 amide and 5'-amido nucleoside analogues as potential inhibitors of the Plasmodium  
849 falciparum dUTPase, Bioorganic Med. Chem., 21 (2013) 5876–5885.
- 850 [39] T. V Mishanina, L. Yu, K. Karunaratne, D. Mondal, An unprecedented mechanism of  
851 nucleotide methylation in organisms containing thyX, Science., 351 (2016) 507–510.
- 852 [40] V.P. Kumar, J.A. Cisneros, K.M. Frey, A. Castellanos-Gonzalez, Y. Wang, A.  
853 Gangjee, A.C. White, W.L. Jorgensen, K.S. Anderson, Structural studies provide clues  
854 for analog design of specific inhibitors of Cryptosporidium hominis thymidylate  
855 synthase-dihydrofolate reductase, Bioorg. Med. Chem. Lett., 24 (2014) 4158–61.
- 856 [41] S. Ferrari, P.M. Costi, R.C. Wade, Inhibitor specificity via protein dynamics: insights  
857 from the design of antibacterial agents targeted against thymidylate synthase, Chem.  
858 Biol., 10 (2003) 1183–1193.
- 859 [42] C.W. Carreras, D. V. Santi, The catalytic mechanism and structure of thymidylate  
860 synthase, Annu. Rev. Biochem., 64 (1995) 721–762.
- 861 [43] D. Tondi, A. Venturelli, S. Ferrari, S. Ghelli, M.P. Costi, Improving specificity vs  
862 bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine, J.  
863 Med. Chem., 48 (2005) 913–916.
- 864 [44] S. Ferrari, V. Losasso, M.P. Costi, Sequence-based identification of specific drug target  
865 regions in the thymidylate synthase enzyme family, ChemMedChem, 3 (2008) 392–  
866 401.
- 867 [45] B.K. Shoichet, R.M. Stroud, D. V Santi, I.D. Kuntz, K.M. Perry, Structure-based  
868 discovery of inhibitors of thymidylate synthase, Science., 259 (1993) 1445–1450.
- 869 [46] J. Finer-Moore, E.B. Fauman, P.G. Foster, K.M. Perry, D. V. Santi, R.M. Stroud,  
870 Refined Structures of Substrate-bound and Phosphate-bound Thymidylate Synthase  
871 from Lactobacillus casei, J. Mol. Biol., 232 (1993) 1101–1116.
- 872 [47] A.C. Anderson, K.M. Perry, D.M. Freymann, R.M. Stroud, The crystal structure of  
873 thymidylate synthase from Pneumocystis carinii reveals a fungal insert important for  
874 drug design, J.Mol.Biol., 297 (2000) 645–657.
- 875 [48] T.J. Stout, D. Tondi, M. Rinaldi, D. Barlocco, P. Pecorari, D. V. Santi, I.D. Kuntz,  
876 R.M. Stroud, B.K. Shoichet, M.P. Costi, Structure-based design of inhibitors specific  
877 for bacterial thymidylate synthase, Biochemistry, 38 (1999) 1607–1617.



- 878 [49] P.M. Costi, M. Rinaldi, D. Tondi, P. Pecorari, D. Barlocco, S. Ghelli, R.M. Stroud, D.  
879 V Santi, T.J. Stout, C. Musiu, E.M. Marangiu, A. Pani, D. Congiu, G.A. Loi, P. La  
880 Colla, Phthalein derivatives as a new tool for selectivity in thymidylate synthase  
881 inhibition, *J. Med. Chem.*, 42 (1999) 2112–2124.
- 882 [50] J.S. Finer-Moore, A.C. Anderson, R.H. O’Neil, M.P. Costi, S. Ferrari, J. Krucinski,  
883 R.M. Stroud, The structure of *Cryptococcus neoformans* thymidylate synthase suggests  
884 strategies for using target dynamics for species-specific inhibition, *Acta Crystallogr.*  
885 *Sect. D Biol. Crystallogr.*, 61 (2005) 1320–1334.
- 886 [51] D. Tondi, U. Slomczynska, M.P. Costi, D.M. Watterson, S. Ghelli, B.K. Shoichet,  
887 Structure-based discovery and in-parallel optimization of novel competitive inhibitors  
888 of thymidylate synthase, *Chem. Biol.*, 6 (1999) 319–31.
- 889 [52] T.A. Fritz, D. Tondi, J.S. Finer-Moore, M.P. Costi, R.M. Stroud, Predicting and  
890 harnessing protein flexibility in the design of species-specific inhibitors of thymidylate  
891 synthase, *Chem. Biol.*, 8 (2001) 981–995.
- 892 [53] M.P. Costi, A. Gelain, D. Barlocco, S. Ghelli, F. Soragni, F. Reniero, T. Rossi, A.  
893 Ruberto, C. Guillou, A. Cavazzuti, C. Casolari, S. Ferrari, Antibacterial agent  
894 discovery using thymidylate synthase biolibrary screening, *J. Med. Chem.*, 49 (2006)  
895 5958–5968.
- 896 [54] S. Mangani, L. Cancian, R. Leone, C. Pozzi, S. Lazzari, R. Luciani, S. Ferrari, M.P.  
897 Costi, Identification of the binding modes of N-phenylphthalimides inhibiting bacterial  
898 thymidylate synthase through X-ray crystallography screening, *J. Med. Chem.*, 54  
899 (2011) 5454–5467.
- 900 [55] S. Ferrari, M. Ingrami, F. Soragni, R.C. Wade, M.P. Costi, Ligand-based discovery of  
901 N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide  
902 derivatives as thymidylate synthase A inhibitors, *Bioorg. Med. Chem. Lett.*, 23 (2013)  
903 663–668.
- 904 [56] S. Ferrari, S. Calò, R. Leone, R. Luciani, L. Costantino, S. Sammak, F. Di Pisa, C.  
905 Pozzi, S. Mangani, M.P. Costi, 2'-Deoxyuridine 5'-Monophosphate Substrate  
906 Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-  
907 2-one Derivatives, *J. Med. Chem.*, 56 (2013) 9356–9360.
- 908 [57] C. Pozzi, S. Ferrari, D. Cortesi, R. Luciani, R.M. Stroud, A. Catalano, M.P. Costi, S.  
909 Mangani, The structure of *Enterococcus faecalis* thymidylate synthase provides clues  
910 about folate bacterial metabolism, *Acta Crystallogr. Sect. D Biol. Crystallogr.*, 68  
911 (2012) 1232–1241.
- 912 [58] S. Calò, D. Tondi, S. Ferrari, A. Venturelli, S. Ghelli, M.P. Costi, Constrained Dansyl  
913 Derivatives Reveal Bacterial Specificity of Highly Conserved Thymidylate Synthases,  
914 *ChemBioChem*, 9 (2008) 779–790.
- 915 [59] H. Myllykallio, G. Lipowski, D. Leduc, J. Filee, P. Forterre, U. Liebl, An Alternative  
916 Flavin-Dependent Mechanism for Thymidylate Synthesis, *Science* (80-. ), 297 (2002)  
917 105–107.
- 918 [60] D. Leduc, S. Graziani, G. Lipowski, C. Marchand, P. Le Maréchal, U. Liebl, H.  
919 Myllykallio, Functional evidence for active site location of tetrameric thymidylate

- 920 synthase X at the interphase of three monomers, *Proc. Natl. Acad. Sci. U. S. A.*, 101  
921 (2004) 7252–7.
- 922 [61] D. Leduc, F. Escartin, H.F. Nijhout, M.C. Reed, U. Liebl, S. Skouloubris, H.  
923 Myllykallio, Flavin-dependent thymidylate synthase ThyX activity: Implications for  
924 the folate cycle in bacteria, *J. Bacteriol.*, 189 (2007) 8537–8545.
- 925 [62] I.I. Mathews, A.M. Deacon, J.M. Canaves, D. McMullan, S. Lesley, S. Agarwalla, P.  
926 Kuhn, Functional analysis of substrate and cofactor complex structures of a  
927 thymidylate synthase-complementing protein, *Structure*, 11 (2003) 677–690.
- 928 [63] S. Graziani, Y. Xia, J.R. Gurnon, J.L. Van Etten, D. Leduc, S. Skouloubris, H.  
929 Myllykallio, U. Liebl, Functional analysis of FAD-dependent thymidylate synthase  
930 ThyX from *Paramecium bursaria* chloroella virus-1, *J. Biol. Chem.*, 279 (2004) 54340–  
931 54347.
- 932 [64] J.H. Hunter, R. Gujjar, C.K.T. Pang, P.K. Rathod, Kinetics and ligand-binding  
933 preferences of *Mycobacterium tuberculosis* thymidylate synthases, ThyA and ThyX,  
934 *PLoS One*, 3 (2008) 1–10.
- 935 [65] E.M. Koehn, T. Fleischmann, J.A. Conrad, B.A. Palfey, S.A. Lesley, I.I. Mathews, A.  
936 Kohen, An unusual mechanism of thymidylate biosynthesis in organisms containing  
937 the thyX gene, *Nature*, 458 (2009) 919–923.
- 938 [66] A. Chernyshev, T. Fleischmann, A. Kohen, Thymidyl biosynthesis enzymes as  
939 antibiotic targets, *Appl. Microbiol. Biotechnol.*, 74 (2007) 282–9.
- 940 [67] J. Rengarajan, C.M. Sasseti, V. Naroditskaya, A. Sloutsky, B.R. Bloom, E.J. Rubin,  
941 The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS)  
942 in mycobacteria, *Mol. Microbiol.*, 53 (2004) 275–282.
- 943 [68] A.S. Fivian-Hughes, J. Houghton, E.O. Davis, *Mycobacterium tuberculosis*  
944 thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA  
945 deletion confers resistance to p-aminosalicylic acid, *Microbiology*, 158 (2012) 308–18.
- 946 [69] P. Sampathkumar, S. Turley, J.E. Ulmer, H.G. Rhie, C.H. Sibley, W.G.J. Hol,  
947 Structure of the *Mycobacterium tuberculosis* flavin dependent thymidylate synthase  
948 (MtbThyX) at 2.0 Å resolution, *J. Mol. Biol.*, 352 (2005) 1091–1104.
- 949 [70] P. Sampathkumar, S. Turley, C.H. Sibley, W.G.J. Hol, NADP<sup>+</sup> expels both the co-  
950 factor and a substrate analog from the *Mycobacterium tuberculosis* ThyX active site:  
951 opportunities for anti-bacterial drug design, *J. Mol. Biol.*, 360 (2006) 1–6.
- 952 [71] K. Wang, Q. Wang, J. Chen, L. Chen, H. Jiang, X. Shen, Crystal structure and  
953 enzymatic characterization of thymidylate synthase X from *Helicobacter pylori* strain  
954 SS1, *Protein Sci.*, 20 (2011) 1398–1410.
- 955 [72] X. Zhang, J. Zhang, G. Guo, X. Mao, Y. Hu, Q. Zou, Crystal structure of a flavin-  
956 dependent thymidylate synthase from *Helicobacter pylori* strain 26695, *Protein Pept.*  
957 *Lett.*, 19 (2012) 1225–1230.
- 958 [73] E.M. Koehn, L.L. Perissinotti, S. Moghram, A. Prabhakar, S. Lesley, I.I. Mathews, A.  
959 Kohen, Folate binding site of flavin-dependent thymidylate synthase, *Proc. Natl. Acad.*  
960 *Sci.*, 109 (2012) 15722–15727.

- 961 [74] I.I. Mathews, Flavin-Dependent Thymidylate Synthase as a Drug Target for Deadly  
962 Microbes: Mutational Study and a Strategy for Inhibitor Design, *J. Bioterror. Biodef.*,  
963 Suppl 12 (2013) 004.
- 964 [75] L. Baugh, I. Phan, D.W. Begley, M.C. Clifton, B. Armour, D.M. Dranow, B.M. Taylor,  
965 M.M. Muruthi, J. Abendroth, J.W. Fairman, D.F. III, S.H. Dieterich, B.L. Staker, A.S.  
966 Gardberg, R. Choi, S.N. Hewitt, A.J. Napuli, J. Myers, L.K. Barrett, Y. Zhang, et al.,  
967 Increasing the structural coverage of tuberculosis drug targets, *Tuberculosis*, 95 (2015)  
968 142–148.
- 969 [76] M. Kögler, B. Vanderhoydonck, S. De Jonghe, J. Rozenski, K. Van Belle, J. Herman,  
970 T. Louat, A. Parchina, C. Sibley, E. Lescrinier, P. Herdewijn, Synthesis and evaluation  
971 of 5-substituted 2'-deoxyuridine monophosphate analogues as inhibitors of flavin-  
972 dependent thymidylate synthase in mycobacterium tuberculosis, *J. Med. Chem.*, 54  
973 (2011) 4847–4862.
- 974 [77] M. Kögler, R. Busson, S. De Jonghe, J. Rozenski, K. Van Belle, T. Louat, H. Munier-  
975 Lehmann, P. Herdewijn, Synthesis and evaluation of 6-Aza-2'-deoxyuridine  
976 monophosphate analogs as inhibitors of thymidylate synthases, and as substrates or  
977 inhibitors of thymidine monophosphate kinase in mycobacterium tuberculosis, *Chem.*  
978 *Biodivers.*, 9 (2012) 536–556.
- 979 [78] A. Parchina, M. Froeyen, L. Margamuljana, J. Rozenski, S. DeJonghe, Y. Briers, R.  
980 Lavigne, P. Herdewijn, E. Lescrinier, Discovery of an acyclic nucleoside phosphonate  
981 that inhibits mycobacterium tuberculosis ThyX based on the binding mode of a 5-  
982 Alkynyl substrate analogue, *ChemMedChem*, 8 (2013) 1373–1383.
- 983 [79] L.A. Alexandrova, V.O. Chekhov, E.R. Shmalenyuk, S.N. Kochetkov, R.A. El-Asrar,  
984 P. Herdewijn, Synthesis and evaluation of C-5 modified 2'-deoxyuridine  
985 monophosphates as inhibitors of M tuberculosis thymidylate synthase, *Bioorg. Med.*  
986 *Chem.*, 23 (2015) 7131–7137.
- 987 [80] E.R. Shmalenyuk, S.N. Kochetkov, L.A. Alexandrova, Novel inhibitors of  
988 Mycobacterium tuberculosis growth based on modified pyrimidine nucleosides and  
989 their analogues, *Russ. Chem. Rev.*, 82 (2013) 896–915.
- 990 [81] S. Graziani, J. Bernauer, S. Skouloubris, M. Graille, C.Z. Zhou, C. Marchand, P.  
991 Decottignies, H. Van Tilbeurgh, H. Myllykallio, U. Liebl, Catalytic mechanism and  
992 structure of viral flavin-dependent thymidylate synthase ThyX, *J. Biol. Chem.*, 281  
993 (2006) 24048–24057.
- 994 [82] F. Esra Önen, Y. Boum, C. Jacquement, M.V. Spanedda, N. Jaber, D. Scherman, H.  
995 Myllykallio, J. Herscovici, Design, synthesis and evaluation of potent thymidylate  
996 synthase X inhibitors, *Bioorganic Med. Chem. Lett.*, 18 (2008) 3628–3631.
- 997 [83] T. Basta, Y. Boum, J. Briffotiaux, H.F. Becker, I. Lamarre-Jouenne, J.-C. Lambry, S.  
998 Skouloubris, U. Liebl, M. Graille, H. van Tilbeurgh, H. Myllykallio, Mechanistic and  
999 structural basis for inhibition of thymidylate synthase ThyX, *Open Biol.*, 2 (2012)  
1000 120120–120120.
- 1001 [84] K. Djaout, I. Lamarre, J. Lambry, K. Anger, J. Briffotiaux, U. Liebl, H. De Reuse, H.  
1002 Myllykallio, Targeting of Helicobacter pylori thymidylate synthase ThyX by non-  
1003 mitotoxic hydroxy-naphthoquinones, *Open Biol.*, 5 (2015) 150015.

- 1004 [85] H.F. Becker, K. Djaout, I. Lamarre, J.E. Ulmer, D. Schaming, V. Balland, U. Liebl, H.  
1005 Myllykallio, M.H. Vos, Substrate interaction dynamics and oxygen control in the active  
1006 site of thymidylate synthase ThyX, *Biochem. J.*, 459 (2014) 37–45.
- 1007 [86] J.E. Ulmer, Y. Boum, C.D. Thouvenel, H. Myllykallio, C.H. Sibley, Functional  
1008 analysis of the *Mycobacterium tuberculosis* FAD-dependent thymidylate synthase,  
1009 ThyX, reveals new amino acid residues contributing to an extended ThyX motif, *J.*  
1010 *Bacteriol.*, 190 (2008) 2056–2064.
- 1011 [87] V. Singh, M. Brecik, R. Mukherjee, J.C. Evans, Z. Svetlíková, J. Blaško, S. Surade, J.  
1012 Blackburn, D.F. Warner, K. Mikušová, V. Mizrahi, The complex mechanism of  
1013 antimycobacterial action of 5-Fluorouracil, *Chem. Biol.*, 22 (2015) 63–75.
- 1014 [88] V.H. Vestereng, J.A. Kovacs, Inability of *Pneumocystis* organisms to incorporate  
1015 bromodeoxyuridine suggests the absence of a salvage pathway for thymidine,  
1016 *Microbiology*, 150 (2004) 1179–1182.
- 1017 [89] J.N. Champness, A. Achari, S.P. Ballantine, P.K. Bryant, C.J. Delves, D.K. Stammers,  
1018 The structure of *Pneumocystis carinii* dihydrofolate reductase to 1.9 Å resolution,  
1019 *Struct. London Engl.* 1993, 2 (1994) 915–924.
- 1020 [90] A. Gangjee, A. Vasudevan, S.F. Queener, R.L. Kisliuk, 2,4-Diamino-5-deaza-6-  
1021 substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical  
1022 inhibitors of dihydrofolate reductases, *J. Med. Chem.*, 39 (1996) 1438–1446.
- 1023 [91] V. Cody, J. Pace, O.A. Namjoshi, A. Gangjee, Structure–activity correlations for three  
1024 pyrido[2,3- *d*]pyrimidine antifolates binding to human and *Pneumocystis carinii*  
1025 dihydrofolate reductase, *Acta Crystallogr. Sect. F Struct. Biol. Commun.*, 71 (2015)  
1026 799–803.
- 1027 [92] A. Gangjee, O.A. Namjoshi, S. Raghavan, S.F. Queener, R.L. Kisliuk, V. Cody,  
1028 Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues  
1029 as antifolates; Application of buchwald-hartwig aminations of heterocycles, *J. Med.*  
1030 *Chem.*, 56 (2013) 4422–4441.
- 1031 [93] A. Gangjee, A.P. Vidwans, A. Vasudevan, S.F. Queener, R.L. Kisliuk, V. Cody, R. Li,  
1032 N. Galitsky, J.R. Luft, W. Pangborn, Structure-based design and synthesis of lipophilic  
1033 2,4-diamino-6- substituted quinazolines and their evaluation as inhibitors of  
1034 dihydrofolate reductases and potential antitumor agents, *J. Med. Chem.*, 41 (1998)  
1035 3426–3434.
- 1036 [94] A. Gangjee, O.O. Adair, M. Pagley, S.F. Queener, N9-Substituted 2,4-  
1037 Diaminoquinazolines: Synthesis and Biological Evaluation of Lipophilic Inhibitors of  
1038 *Pneumocystis carinii* and *Toxoplasma gondii* Dihydrofolate Reductase, *J. Med. Chem.*,  
1039 51 (2008) 6195–6200.
- 1040 [95] A. Gangjee, H.D. Jain, J. Phan, X. Guo, S.F. Queener, R.L. Kisliuk, 2,4-Diamino-5-  
1041 methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and  
1042 nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate  
1043 reductase inhibitors, *Bioorg. Med. Chem.*, 18 (2010) 953–61.
- 1044 [96] E.W. Barrow, P.C. Bourne, W.W. Barrow, Functional Cloning of *Bacillus anthracis*  
1045 Dihydrofolate Reductase and Confirmation of Natural Resistance to Trimethoprim

- 1046 Functional Cloning of Bacillus anthracis Dihydrofolate Reductase and Confirmation of  
1047 Natural Resistance to Trimethoprim, 48 (2004) 4643–4649.
- 1048 [97] T.M. Joska, A.C. Anderson, Structure-activity relationships of Bacillus cereus and  
1049 Bacillus anthracis dihydrofolate reductase: Toward the identification of new potent  
1050 drug leads, Antimicrob. Agents Chemother., 50 (2006) 3435–3443.
- 1051 [98] E.W. Barrow, J. Dreier, S. Reinelt, P.C. Bourne, W.W. Barrow, In vitro efficacy of  
1052 new antifolates against trimethoprim-resistant Bacillus anthracis, Antimicrob. Agents  
1053 Chemother., 51 (2007) 4447–4452.
- 1054 [99] J.M. Beierlein, K.M. Frey, D.B. Bolstad, P.M. Pelphey, T.M. Joska, A.E. Smith, N.D.  
1055 Priestley, D.L. Wright, A.C. Anderson, Synthetic and crystallographic studies of a new  
1056 inhibitor series targeting Bacillus anthracis dihydrofolate reductase, J. Med. Chem., 51  
1057 (2008) 7532–7540.
- 1058 [100] B.C. Bennett, H. Xu, R.F. Simmerman, R.E. Lee, C.G. Dealwis, Crystal structure of  
1059 the anthrax drug target, Bacillus anthracis dihydrofolate reductase, J. Med. Chem., 50  
1060 (2007) 4374–4381.
- 1061 [101] J.M. Beierlein, L. Deshmukh, K.M. Frey, O. Vinogradova, A.C. Anderson, The  
1062 solution structure of Bacillus anthracis dihydrofolate reductase yields insight into the  
1063 analysis of structure-activity relationships for novel inhibitors, Biochemistry, 48 (2009)  
1064 4100–4108.
- 1065 [102] J.M. Beierlein, N.G. Karri, A.C. Anderson, Targeted mutations of bacillus anthracis  
1066 dihydrofolate reductase condense complex structure-activity relationships, J. Med.  
1067 Chem., 53 (2010) 7327–7336.
- 1068 [103] C.R. Bourne, R.A. Bunce, P.C. Bourne, K.D. Berlin, E.W. Barrow, W.W. Barrow,  
1069 Crystal structure of Bacillus anthracis dihydrofolate reductase with the  
1070 dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural  
1071 explanation of potency and selectivity, Antimicrob. Agents Chemother., 53 (2009)  
1072 3065–3073.
- 1073 [104] B. Nammalwar, R.A. Bunce, K.D. Berlin, C.R. Bourne, P.C. Bourne, E.W. Barrow,  
1074 W.W. Barrow, Synthesis and biological activity of substituted 2,4-diaminopyrimidines  
1075 that inhibit Bacillus anthracis, Eur. J. Med. Chem., 54 (2012) 387–396.
- 1076 [105] B. Nammalwar, C.R. Bourne, R.A. Bunce, N. Wakeham, P.C. Bourne, K. Ramnarayan,  
1077 S. Mylvaganam, K.D. Berlin, E.W. Barrow, W.W. Barrow, Inhibition of Bacterial  
1078 Dihydrofolate Reductase by 6-Alkyl-2,4-diaminopyrimidines, ChemMedChem, 7  
1079 (2012) 1974–1982.
- 1080 [106] C.R. Bourne, N. Wakeham, B. Nammalwar, V. Tseitin, P.C. Bourne, E.W. Barrow, S.  
1081 Mylvaganam, K. Ramnarayan, R.A. Bunce, K.D. Berlin, W.W. Barrow, Structure-  
1082 activity relationship for enantiomers of potent inhibitors of B anthracis dihydrofolate  
1083 reductase, Biochim. Biophys. Acta - Proteins Proteomics, 1834 (2013) 46–52.
- 1084 [107] B. Nammalwar, N. Muddala, C. Bourne, M. Henry, P. Bourne, R. Bunce, E. Barrow,  
1085 K. Berlin, W. Barrow, Synthesis and Biological Evaluation of 2,4-Diaminopyrimidine-  
1086 Based Antifolate Drugs against Bacillus anthracis, Molecules, 19 (2014) 3231–3246.
- 1087 [108] B. Nammalwar, C.R. Bourne, N. Wakeham, P.C. Bourne, E.W. Barrow, N.P. Muddala,

- 1088 R.A. Bunce, K.D. Berlin, W.W. Barrow, Modified 2,4-diaminopyrimidine-based  
1089 dihydrofolate reductase inhibitors as potential drug scaffolds against *Bacillus anthracis*,  
1090 *Bioorg. Med. Chem.*, 23 (2015) 203–211.
- 1091 [109] N. Muddala, B. Nammalwar, S. Selvaraju, C. Bourne, M. Henry, R. Bunce, K. Berlin,  
1092 E. Barrow, W. Barrow, Evaluation of New Dihydrophthalazine-Appended 2,4-  
1093 Diaminopyrimidines against *Bacillus anthracis*: Improved Syntheses Using a New  
1094 Pincer Complex, *Molecules*, 20 (2015) 7222–7244.
- 1095 [110] C.R. Bourne, N. Wakeham, N. Webb, B. Nammalwar, R.A. Bunce, K.D. Berlin, W.W.  
1096 Barrow, The structure and competitive substrate inhibition of dihydrofolate reductase  
1097 from *enterococcus faecalis* reveal restrictions to cofactor docking, *Biochemistry*, 53  
1098 (2014) 1228–1238.
- 1099 [111] A. Morgan, C. Cofer, D.L. Stevens, Iclaprim: a novel dihydrofolate reductase inhibitor  
1100 for skin and soft tissue infections, *Futur. Microbiology*, 4 (2009) 131–144.
- 1101 [112] M. Kurosu, S. Siricilla, K. Mitachi, Advances in MRSA drug discovery: where are we  
1102 and where do we need to be?, *Expert Opin Drug Discov*, 8 (2013) 1095–1116.
- 1103 [113] C.R. Bourne, E.W. Barrow, R.A. Bunce, P.C. Bourne, K.D. Berlin, W.W. Barrow,  
1104 Inhibition of antibiotic-resistant *Staphylococcus aureus* by the broad-spectrum  
1105 dihydrofolate reductase inhibitor RAB1, *Antimicrob. Agents Chemother.*, 54 (2010)  
1106 3825–3833.
- 1107 [114] P.M. Pelphrey, V.M. Popov, T.M. Joska, J.M. Beierlein, E.S.D. Bolstad, Y.A.  
1108 Fillingham, D.L. Wright, A.C. Anderson, Highly efficient ligands for dihydrofolate  
1109 reductase from *Cryptosporidium hominis* and *Toxoplasma gondii* inspired by structural  
1110 analysis, *J. Med. Chem.*, 50 (2007) 940–50.
- 1111 [115] J. Liu, D.B. Bolstad, A.E. Smith, N.D. Priestley, D.L. Wright, A.C. Anderson,  
1112 Structure-Guided Development of Efficacious Antifungal Agents Targeting *Candida*  
1113 *glabrata* Dihydrofolate Reductase, *Chem. Biol.*, 15 (2008) 990–996.
- 1114 [116] K.M. Frey, J. Liu, M.N. Lombardo, D.B. Bolstad, D.L. Wright, A.C. Anderson, Crystal  
1115 Structures of Wild-type and Mutant Methicillin-resistant *Staphylococcus aureus*  
1116 Dihydrofolate Reductase Reveal an Alternate Conformation of NADPH That May Be  
1117 Linked to Trimethoprim Resistance, *J. Mol. Biol.*, 387 (2009) 1298–1308.
- 1118 [117] K. Viswanathan, K.M. Frey, E.W. Scocchera, B.D. Martin, P.W. Swain, J.B. Alverson,  
1119 N.D. Priestley, A.C. Anderson, D.L. Wright, Toward new therapeutics for skin and soft  
1120 tissue infections: Propargyl-Linked antifolates are potent inhibitors of MRSA and  
1121 *streptococcus pyogenes*, *PLoS One*, 7 (2012) 1–9.
- 1122 [118] K.M. Frey, K. Viswanathan, D.L. Wright, A.C. Anderson, Prospective screening of  
1123 novel antibacterial inhibitors of dihydrofolate reductase for mutational resistance,  
1124 *Antimicrob. Agents Chemother.*, 56 (2012) 3556–3562.
- 1125 [119] K.M. Lamb, N. G-Dayanandan, D.L. Wright, A.C. Anderson, Elucidating features that  
1126 drive the design of selective antifolates using crystal structures of human dihydrofolate  
1127 reductase, *Biochemistry*, 52 (2013) 7318–7326.
- 1128 [120] S. Keshipeddy, S.M. Reeve, A.C. Anderson, D.L. Wright, Non-racemic Antifolates  
1129 Stereo-selectively Recruit Alternate Cofactors and Overcome Resistance in *S aureus*, *J.*

- 1130 Am. Chem. Soc., (2015) 150622174016006.
- 1131 [121] K.M. Lamb, M.N. Lombardo, J. Alverson, N.D. Priestley, D.L. Wright, A.C.  
1132 Anderson, Crystal structures of klebsiella pneumoniae dihydrofolate reductase bound  
1133 to propargyl-linked antifolates reveal features for potency and selectivity, Antimicrob.  
1134 Agents Chemother., 58 (2014) 7484–7491.
- 1135 [122] S. Khabnadideh, D. Pez, A. Musso, R. Brun, L.M. Ruiz Pérez, D. González-  
1136 Pacanowska, I.H. Gilbert, Design, synthesis and evaluation of 2,4-diaminoquinazolines  
1137 as inhibitors of trypanosomal and leishmanial dihydrofolate reductase, Bioorganic  
1138 Med. Chem., 13 (2005) 2637–2649.
- 1139 [123] X. Li, M. Hilgers, M. Cunningham, Z. Chen, M. Trzoss, J. Zhang, L. Kohnen, T. Lam,  
1140 C. Creighton, K. Gc, K. Nelson, B. Kwan, M. Stidham, V. Brown-Driver, K.J. Shaw, J.  
1141 Finn, Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-  
1142 diaminoquinazolines, Bioorganic Med. Chem. Lett., 21 (2011) 5171–5176.
- 1143 [124] T. Lam, M.T. Hilgers, M.L. Cunningham, B.P. Kwan, K.J. Nelson, V. Brown-Driver,  
1144 V. Ong, M. Trzoss, G. Hough, K.J. Shaw, J. Finn, Structure-based design of new  
1145 dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-  
1146 diaminoquinazolines, J. Med. Chem., 57 (2014) 651–668.
- 1147 [125] M. Kobayashi, T. Kinjo, Y. Koseki, C.R. Bourne, W.W. Barrow, S. Aoki,  
1148 Identification of novel potential antibiotics against Staphylococcus using structure-  
1149 based drug screening targeting dihydrofolate reductase, J. Chem. Inf. Model., 54 (2014)  
1150 1242–1253.
- 1151 [126] I. Chatterjee, A. Kriegeskorte, A. Fischer, S. Deiwick, N. Theimann, R.A. Proctor, G.  
1152 Peters, M. Herrmann, B.C. Kahl, In vivo mutations of thymidylate synthase (Encoded  
1153 by thyA) are responsible for thymidine dependency in clinical small-colony variants of  
1154 Staphylococcus aureus, J. Bacteriol., 190 (2008) 834–842.
- 1155 [127] A. Kriegeskorte, N.I. Lorè, A. Bragonzi, C. Riva, M. Kelkenberg, K. Becker, R.A.  
1156 Proctor, G. Peters, B.C. Kahl, Thymidine-Dependent Staphylococcus aureus Small-  
1157 Colony Variants Are Induced by Trimethoprim-Sulfamethoxazole (SXT) and Have  
1158 Increased Fitness during SXT Challenge, Antimicrob. Agents Chemother., 59 (2015)  
1159 7265–72.
- 1160 [128] S. Besier, J. Zander, B.C. Kahl, P. Kraiczy, V. Brade, T.A. Wichelhaus, The  
1161 thymidine-dependent small-colony-variant phenotype is associated with  
1162 hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates,  
1163 Antimicrob. Agents Chemother., 52 (2008) 2183–2189.
- 1164 [129] Q. Zhang, T. Nguyen, M. McMichael, S.E. Velu, J. Zou, X. Zhou, H. Wu, New small-  
1165 molecule inhibitors of dihydrofolate reductase inhibit Streptococcus mutans, Int. J.  
1166 Antimicrob. Agents, 46 (2015) 174–182.
- 1167 [130] S. Chakraborty, T. Gruber, C.E. Barry, H.I. Boshoff, K.Y. Rhee, Para-aminosalicylic  
1168 acid acts as an alternative substrate of folate metabolism in Mycobacterium  
1169 tuberculosis, Science, 339 (2013) 88–91.
- 1170 [131] J. Zheng, E.J. Rubin, P. Bifani, V. Mathys, V. Lim, M. Au, J. Jang, J. Nam, T. Dick,  
1171 J.R. Walker, K. Pethe, L.R. Camacho, Para-aminosalicylic acid is a prodrug targeting

- 1172 dihydrofolate reductase in mycobacterium tuberculosis, J. Biol. Chem., 288 (2013)  
1173 23447–23456.
- 1174 [132] M.R. Nixon, K.W. Saionz, M.S. Koo, M.J. Szymonifka, H. Jung, J.P. Roberts, M.  
1175 Nandakumar, A. Kumar, R. Liao, T. Rustad, J.C. Sacchettini, K.Y. Rhee, J.S.  
1176 Freundlich, D.R. Sherman, Folate pathway disruption leads to critical disruption of  
1177 methionine derivatives in mycobacterium tuberculosis, Chem. Biol., 21 (2014) 819–  
1178 830.
- 1179 [133] V. Mathys, R. Wintjens, P. Lefevre, J. Bertout, A. Singhal, M. Kiass, N. Kurepina,  
1180 X.M. Wang, B. Mathema, A. Baulard, B.N. Kreiswirth, P. Bifani, Molecular genetics  
1181 of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of  
1182 Mycobacterium tuberculosis, Antimicrob. Agents Chemother., 53 (2009) 2100–2109.
- 1183 [134] F. Zhao, X. De Wang, L.N. Erber, M. Luo, A.Z. Guo, S.S. Yang, J. Gu, B.J. Turman,  
1184 Y.R. Gao, D.F. Li, Z.Q. Cui, Z.P. Zhang, L.J. Bi, A.D. Baughn, X.E. Zhang, J.Y.  
1185 Deng, Binding pocket alterations in dihydrofolate synthase confer resistance to para-  
1186 aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis, Antimicrob.  
1187 Agents Chemother., 58 (2014) 1479–1487.
- 1188 [135] Y. Minato, J.M. Thiede, S.L. Kordus, E.J. McKlveen, B.J. Turman, A.D. Baughn,  
1189 Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-  
1190 aminosalicylic acid susceptibility and resistance, Antimicrob. Agents Chemother., 59  
1191 (2015) 5097–5106.
- 1192 [136] Y.-S. Cheng, J.C. Sacchettini, Structural Insights into *Mycobacterium tuberculosis*  
1193 Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to  
1194 para -Aminosalicylic Acid Resistance, Biochemistry, (2016) acs.biochem.5b00993.
- 1195 [137] K.A. Wolff, L. Nguyen, Strategies for potentiation of ethionamide and folate  
1196 antagonists against Mycobacterium tuberculosis, Expert Rev. Anti. Infect. Ther., 10  
1197 (2012) 971–81.
- 1198 [138] L.B. Gerum, J.E. Ulmer, D.P. Jacobus, N.P. Jensen, D.R. Sherman, C.H. Sibley, Novel  
1199 Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit  
1200 Mycobacterium tuberculosis dihydrofolate reductase Novel Saccharomyces cerevisiae  
1201 screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis  
1202 dihydrofolate red, Society, 46 (2002) 3362–3369.
- 1203 [139] A. Kumar, M. Zhang, L. Zhu, R.P. Liao, C. Mutai, S. Hafsai, D.R. Sherman, M.-W.  
1204 Wang, High-throughput Screening and Sensitized Bacteria Identify an M tuberculosis  
1205 Dihydrofolate Reductase Inhibitor with Whole Cell Activity, PLoS One, 7 (2012)  
1206 e39961.
- 1207 [140] R. Li, R. Sirawaraporn, P. Chitnumsub, W. Sirawaraporn, J. Wooden, F. Athappilly, S.  
1208 Turley, W.G. Hol, Three-dimensional structure of M tuberculosis dihydrofolate  
1209 reductase reveals opportunities for the design of novel tuberculosis drugs, J. Mol. Biol.,  
1210 295 (2000) 307–323.
- 1211 [141] M.H.R.I. El-Hamamsy, A.W. Smith, A.S. Thompson, M.D. Threadgill, Structure-based  
1212 design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate  
1213 reductase from Mycobacterium tuberculosis, Bioorg. Med. Chem., 15 (2007) 4552–76.



- 1214 [142] W. Hong, Y. Wang, Z. Chang, Y. Yang, J. Pu, T. Sun, S. Kaur, J.C. Sacchettini, H.  
1215 Jung, W. Lin Wong, L. Fah Yap, Y. Fong Ngeow, I.C. Paterson, H. Wang, The  
1216 identification of novel *Mycobacterium tuberculosis* DHFR inhibitors and the  
1217 investigation of their binding preferences by using molecular modelling, *Sci. Rep.*, 5  
1218 (2015) 15328.
- 1219 [143] A. Kumar, A. Guardia, G. Colmenarejo, E. Pérez, R.R. Gonzalez, P. Torres, D. Calvo,  
1220 R.M. Gómez, F. Ortega, E. Jiménez, R.C. Gabarro, J. Rullás, L. Ballell, D.R. Sherman,  
1221 A Focused Screen Identifies Antifolates with Activity on *Mycobacterium tuberculosis*,  
1222 *ACS Infect. Dis.*, (2015) acsinfecdis.5b00063.
- 1223 [144] A.C. Lele, A. Raju, M.K. Ray, M.G.R. Rajan, M.S. Degani, Design and Synthesis of  
1224 Diaminotriazines as Anti-Tuberculosis DHFR Inhibitors, *Curr. Res. Drug Discov.*, 1  
1225 (2014) 45–50.
- 1226 [145] N.R. Tawari, S. Bag, A. Raju, A.C. Lele, R. Bairwa, M.K. Ray, M. Rajan, L.U.  
1227 Nawale, D. Sarkar, M.S. Degani, Rational drug design, synthesis and biological  
1228 evaluation of dihydrofolate reductase inhibitors as antituberculosis agents, *Future Med.*  
1229 *Chem.*, 7 (2015) 979–988.
- 1230 [146] A.C. Lele, A. Raju, M.P. Khambete, M.K. Ray, M.G.R. Rajan, M.A. Arkile, N.J.  
1231 Jadhav, D. Sarkar, M.S. Degani, Design and Synthesis of a Focused Library of  
1232 Diamino Triazines as Potential *Mycobacterium tuberculosis* DHFR Inhibitors, *ACS*  
1233 *Med. Chem. Lett.*, 6 (2015) 1140–1144.
- 1234 [147] G. Mugumbate, K.A. Abrahams, J.A.G. Cox, G. Papadatos, G. van Westen, J. Lelièvre,  
1235 S.T. Calus, N.J. Loman, L. Ballell, D. Barros, J.P. Overington, G.S. Besra,  
1236 *Mycobacterial dihydrofolate reductase inhibitors identified using chemogenomic*  
1237 *methods and in vitro validation*, *PLoS One*, 10 (2015) e0121492.
- 1238 [148] L.F. Kuyper, D.P. Baccanari, M.L. Jones, R.N. Hunter, R.L. Tansik, S.S. Joyner, C.M.  
1239 Boytos, S.K. Rudolph, V. Knick, H.R. Wilson, J.M. Caddell, H.S. Friedman, J.C.W.  
1240 Comley, J.N. Stables, High-affinity inhibitors of dihydrofolate reductase:  
1241 Antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-  
1242 f]quinazolines with small molecular size, *J. Med. Chem.*, 39 (1996) 892–903.
- 1243 [149] T. Otzen, E.G. Wempe, B. Kunz, R. Bartels, G. Lehwark-Yvetot, W. Hänsel, K.J.  
1244 Schaper, J.K. Seydel, Folate-Synthesizing Enzyme System as Target for Development  
1245 of Inhibitors and Inhibitor Combinations against *Candida albicans* - Synthesis and  
1246 Biological Activity of New 2,4-Diaminopyrimidines and 4'-Substituted 4-  
1247 Aminodiphenyl Sulfones, *J. Med. Chem.*, 47 (2004) 240–253.
- 1248 [150] J.L. Paulsen, J. Liu, D.B. Bolstad, A.E. Smith, N.D. Priestley, D.L. Wright, A.C.  
1249 Anderson, In vitro biological activity and structural analysis of 2,4-diamino-5-(2'-  
1250 arylpropargyl)pyrimidine inhibitors of *Candida albicans*, *Bioorganic Med. Chem.*, 17  
1251 (2009) 4866–4872.
- 1252 [151] J. Liu, D.B. Bolstad, A.E. Smith, N.D. Priestley, D.L. Wright, A.C. Anderson, Probing  
1253 the active site of *Candida glabrata* dihydrofolate reductase with high resolution crystal  
1254 structures and the synthesis of new inhibitors, *Chem. Biol. Drug Des.*, 73 (2009) 62–  
1255 74.
- 1256 [152] J.L. Paulsen, S.D. Bendel, A.C. Anderson, Crystal Structures of *Candida albicans*

- 1257 Dihydrofolate Reductase Bound to Propargyl-Linked Antifolates Reveal the Flexibility  
1258 of Active Site Loop Residues Critical for Ligand Potency and Selectivity, *Chem. Biol.*  
1259 *Drug Des.*, 78 (2011) 505–512.
- 1260 [153] J.L. Paulsen, K. Viswanathan, D.L. Wright, A.C. Anderson, Structural analysis of the  
1261 active sites of dihydrofolate reductase from two species of *Candida* uncovers ligand-  
1262 induced conformational changes shared among species, *Bioorganic Med. Chem. Lett.*,  
1263 23 (2013) 1279–1284.
- 1264 [154] N. G-Dayananandan, J.L. Paulsen, K. Viswanathan, S. Keshipeddy, M.N. Lombardo, W.  
1265 Zhou, K.M. Lamb, A.E. Sochia, J.B. Alverson, N.D. Priestley, D.L. Wright, A.C.  
1266 Anderson, Propargyl-linked antifolates are dual inhibitors of *Candida albicans* and  
1267 *Candida glabrata*, *J. Med. Chem.*, 57 (2014) 2643–2656.
- 1268 [155] Y.T. Kumar, Sivakumar Prasanth Jasrai, H.A. Pandya, Applications of Receptor- and  
1269 Ligand-based Models in Inverse Docking Experiments: Recognition of Dihydrofolate  
1270 Reductase using 7, 8-dialkyl-1,3-diaminopyrrolo[3, 2-f]quinazolines, *Curr. Comput.*  
1271 *Aided-Drug Des.*, 12 (2015) 1–14.
- 1272 [156] K.M. Ivanetich, D. V. Santi, Bifunctional thymidylate synthase-dihydrofolate reductase  
1273 in protozoa, *Exp. Parasitol.*, 70 (1990) 367–371.
- 1274 [157] C.K.T. Pang, S.K. De, J. White, F.S. Buckner, G. Varani, P.K. Rathod, Differential  
1275 drug binding by the highly conserved *Plasmodium falciparum* thymidylate synthase,  
1276 *Mol. Biochem. Parasitol.*, 143 (2005) 121–124.
- 1277 [158] D.R. Knighton, C.-C. Kan, E. Howland, C.A. Janson, Z. Hostomska, K.M. Welsh, D.A.  
1278 Matthews, Structure of and kinetic channelling in bifunctional dihydrofolate reductase–  
1279 thymidylate synthase, *Nat. Struct. Mol. Biol.*, 1 (1994) 186 – 194.
- 1280 [159] W. Edward Martucci, M. Udier-Blagovic, C. Atreya, O. Babatunde, M.A. Vargo, W.L.  
1281 Jorgensen, K.S. Anderson, Novel non-active site inhibitor of *Cryptosporidium hominis*  
1282 TS-DHFR identified by a virtual screen, *Bioorganic Med. Chem. Lett.*, 19 (2009) 418–  
1283 423.
- 1284 [160] W.E. Martucci, J.M. Rodriguez, M.A. Vargo, M. Marr, A.D. Hamilton, K.S. Anderson,  
1285 Exploring novel strategies for AIDS protozoal pathogens:  $\alpha$ -helix mimetics targeting a  
1286 key allosteric protein-protein interaction in *C. hominis* TS-DHFR, *Med. Chem.*  
1287 *Commun.*, 4 (2013) 1247–1256.
- 1288 [161] H. Sharma, M.J. Landau, T.J. Sullivan, V.P. Kumar, M.K. Dahlgren, W.L. Jorgensen,  
1289 K.S. Anderson, Virtual screening reveals allosteric inhibitors of the *Toxoplasma gondii*  
1290 thymidylate synthase-dihydrofolate reductase, *Bioorg. Med. Chem. Lett.*, 24 (2014)  
1291 1232–5.
- 1292 [162] M.J. Landau, H. Sharma, K.S. Anderson, Selective peptide inhibitors of bifunctional  
1293 thymidylate synthase-dihydrofolate reductase from *Toxoplasma gondii* provide insights  
1294 into domain-domain communication and allosteric regulation, *Protein Sci.*, 22 (2013)  
1295 1161–73.
- 1296 [163] Y. Yuthavong, B. Tarnchompoo, T. Vilaivan, P. Chitnumsub, S. Kamchonwongpaisan,  
1297 S.A. Charman, D.N. McLennan, K.L. White, L. Vivas, E. Bongard, C.  
1298 Thongphanchang, S. Taweechai, J. Vanichtanankul, R. Rattanajak, U. Arwon, P.

- 1299 Fantauzzi, J. Yuvaniyama, W.N. Charman, D. Matthews, Malarial dihydrofolate  
1300 reductase as a paradigm for drug development against a resistance-compromised target,  
1301 Proc. Natl. Acad. Sci., 109 (2012) 16823–16828.
- 1302 [164] J. Yuvaniyama, P. Chitnumsub, S. Kamchonwongpaisan, J. Vanichtanankul, W.  
1303 Sirawaraporn, P. Taylor, M.D. Walkinshaw, Y. Yuthavong, Insights into antifolate  
1304 resistance from malarial DHFR-TS structures, Nat. Struct. Biol., 10 (2003) 357–365.
- 1305 [165] N. Drinkwater, S. McGowan, From crystal to compound: structure-based antimalarial  
1306 drug discovery, Biochem. J., 461 (2014) 349–69.
- 1307 [166] S. Abbat, V. Jain, P. V Bharatam, Origins of the specificity of inhibitor P218 toward  
1308 wild-type and mutant PfDHFR: a molecular dynamics analysis, J. Biomol. Struct.  
1309 Dyn., (2014) 1–16.
- 1310 [167] R. Giridhar, R.S. Tamboli, D.G. Prajapati, S. Soni, S. Gupta, M.R. Yadav, Synthesis of  
1311 novel 4,6-diaryl-2-aminopyrimidines as potential antiplasmodial agents, Med. Chem.  
1312 Res., 22 (2013) 3309–3315.
- 1313 [168] B. Borkakoty, K. Sarma, P. Parida, A. Prakash, P. Kishore Mohapatra, J. Mahanta, In  
1314 Silico Screening of Antifolate Based Novel Inhibitors from Brucea mollis Wall ex kurz  
1315 Against Quadruple Mutant Drug Resistant PfDHFR, Comb. Chem. High Throughput  
1316 Screen., 17 (2014) 681–693.
- 1317 [169] W. Mokmak, S. Chunsrivirod, S. Hannongbua, Y. Yuthavong, S. Tongsima, S.  
1318 Kamchonwongpaisan, Molecular dynamics of interactions between rigid and flexible  
1319 antifolates and dihydrofolate reductase from pyrimethamine-sensitive and  
1320 pyrimethamine-resistant Plasmodium falciparum, Chem. Biol. Drug Des., 84 (2014)  
1321 450–461.
- 1322 [170] L. Adane, S. Bhagat, M. Arfeen, S. Bhatia, R. Sirawaraporn, W. Sirawaraporn, A.K.  
1323 Chakraborti, P. V. Bharatam, Design and synthesis of guanylthiourea derivatives as  
1324 potential inhibitors of Plasmodium falciparum dihydrofolate reductase enzyme,  
1325 Bioorganic Med. Chem. Lett., 24 (2014) 613–617.
- 1326 [171] A. Heinberg, E. Siu, C. Stern, E.A. Lawrence, M.T. Ferdig, K.W. Deitsch, L.A.  
1327 Kirkman, Direct evidence for the adaptive role of copy number variation on antifolate  
1328 susceptibility in Plasmodium falciparum, Mol. Microbiol., 88 (2013) 702–712.
- 1329 [172] D.J. Bzik, W.B. Li, T. Horii, J. Inselburg, Molecular cloning and sequence analysis of  
1330 the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene, Proc.  
1331 Natl. Acad. Sci. U. S. A., 84 (1987) 8360–4.
- 1332 [173] W. Sirawaraporn, R. Sertsrivanich, R.G. Booth, C. Hansch, R.A. Neal, D. V. Santi,  
1333 Selective inhibition of Leishmania dihydrofolate reductase and Leishmania growth by  
1334 5-benzyl-2,4-diaminopyrimidines, Mol. Biochem. Parasitol., 31 (1988) 79–85.
- 1335 [174] S.F. Chowdhury, V.B. Villamor, R.H. Guerrero, I. Leal, R. Brun, S.L. Croft, J.M.  
1336 Goodman, L. Maes, L.M. Ruiz-Perez, D.G. Pacanowska, I.H. Gilbert, Design,  
1337 synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate  
1338 reductase, J. Med. Chem., 42 (1999) 4300–4312.
- 1339 [175] L. Maganti, P. Manoharan, N. Ghoshal, Probing the structure of Leishmania donovani  
1340 chagasi DHFR-TS: Comparative protein modeling and protein-ligand interaction

- 1341 studies, *J. Mol. Model.*, 16 (2010) 1539–1547.
- 1342 [176] R. Rajasekaran, Y.P.P. Chen, Probing the structure of *Leishmania major* DHFR TS and  
1343 structure based virtual screening of peptide library for the identification of anti-  
1344 Leishmanial leads, *J. Mol. Model.*, 18 (2012) 4089–4100.
- 1345 [177] P. Palit, A. Hazra, A. Maity, R.S.K. Vijayan, P. Manoharan, S. Banerjee, N.B. Mondal,  
1346 N. Ghoshal, N. Ali, Discovery of safe and orally effective 4-aminoquinoline  
1347 analogues as apoptotic inducers with activity against experimental visceral  
1348 leishmaniasis, *Antimicrob. Agents Chemother.*, 56 (2012) 432–445.
- 1349 [178] S.F. Chowdhury, R.H. Guerrero, R. Brun, L.M. Ruiz-Perez, D.G. Pacanowska, I.H.  
1350 Gilbert, Synthesis and testing of 5-benzyl-2,4-diaminopyrimidines as potential  
1351 inhibitors of leishmanial and trypanosomal dihydrofolate reductase, *J Enzym. Inhib*  
1352 *Med Chem*, 17 (2002) 293–302.
- 1353 [179] D. Pez, I. Leal, F. Zuccotto, C. Boussard, R. Brun, S.L. Croft, V. Yardley, L.M. Ruiz  
1354 Perez, D. Gonzalez Pacanowska, I.H. Gilbert, 2,4-Diaminopyrimidines as inhibitors of  
1355 leishmanial and trypanosomal dihydrofolate reductase, *Bioorganic Med. Chem.*, 11  
1356 (2003) 4693–4711.
- 1357 [180] O. Senkovich, V. Bhatia, N. Garg, O. Senkovich, V. Bhatia, N. Garg, Lipophilic  
1358 Antifolate Trimetrexate Is a Potent Inhibitor of *Trypanosoma cruzi* : Prospect for  
1359 Chemotherapy of Chagas ' Disease Lipophilic Antifolate Trimetrexate Is a Potent  
1360 Inhibitor of *Trypanosoma cruzi* : Prospect for Chemotherapy of Chagas ' Disease, 49  
1361 (2005) 3234–3238.
- 1362 [181] N. Schormann, O. Senkovich, K. Walker, D.L. Wright, A.C. Anderson, A. Rosowsky,  
1363 S. Ananthan, B. Shinkre, S. Velu, D. Chattopadhyay, Structure-based approach to  
1364 pharmacophore identification, in silico screening, and three-dimensional quantitative  
1365 structure-activity relationship studies for inhibitors of *Trypanosoma cruzi* dihydrofolate  
1366 reductase function, *Proteins*, 73 (2008) 889–901.
- 1367 [182] O. Senkovich, N. Schormann, D. Chattopadhyay, Structures of dihydrofolate reductase-  
1368 thymidylate synthase of *trypanosoma cruzi* in the folate-free state and in complex with  
1369 two antifolate drugs, trimetrexate and methotrexate, *Acta Crystallogr. Sect. D Biol.*  
1370 *Crystallogr.*, 65 (2009) 704–716.
- 1371 [183] P. Chitnumsub, J. Yuvaniyama, T. Chahomchuen, T. Vilaivan, Y. Yuthavong,  
1372 Crystallization and preliminary crystallographic studies of dihydrofolate reductase-  
1373 thymidylate synthase from *Trypanosoma cruzi*, the Chagas disease pathogen, *Acta*  
1374 *Crystallogr. Sect. F. Struct. Biol. Cryst. Commun.*, 65 (2009) 1175–8.
- 1375 [184] N. Schormann, S.E. Velu, S. Murugesan, O. Senkovich, K. Walker, B.C. Chenna, B.  
1376 Shinkre, A. Desai, D. Chattopadhyay, Synthesis and characterization of potent  
1377 inhibitors of *Trypanosoma cruzi* dihydrofolate reductase, *Bioorg. Med. Chem.*, 18  
1378 (2010) 4056–4066.
- 1379 [185] J. Vanichtanankul, S. Taweechai, J. Yuvaniyama, T. Vilaivan, P. Chitnumsub, S.  
1380 Kamchonwongpaisan, Y. Yuthavong, Trypanosomal dihydrofolate reductase reveals  
1381 natural antifolate resistance, *ACS Chem. Biol.*, 6 (2011) 905–911.
- 1382 [186] B.A. Fox, D.J. Bzik, De novo pyrimidine biosynthesis is required for virulence of

- 1383            *Toxoplasma gondii*, *Nature*, 415 (2002) 926–9.
- 1384    [187] M.H. Iltzsch, Pyrimidine salvage pathways in *Toxoplasma gondii*, *J. Eukaryot.*  
1385            *Microbiol.*, 40 (1993) 24–8.
- 1386    [188] A. Gangjee, W. Li, J. Yang, R.L. Kisliuk, Design, synthesis, and biological evaluation  
1387            of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-  
1388            d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors, *J.*  
1389            *Med. Chem.*, 51 (2008) 68–76.
- 1390    [189] D. Pacheco Homem, R. Flores, P. Tosqui, T. de Castro Rozada, E. Abicht Basso, A.  
1391            Gasparotto, F. Augusto Vicente Seixas, Homology modeling of dihydrofolate reductase  
1392            from *T. gondii* bonded to antagonists: molecular docking and molecular dynamics  
1393            simulations, *Mol. Biosyst.*, 9 (2013) 1308–15.
- 1394    [190] N. Zaware, H. Sharma, J. Yang, R.K.V. Devambatla, S.F. Queener, K.S. Anderson, A.  
1395            Gangjee, Discovery of potent and selective inhibitors of *toxoplasma gondii* thymidylate  
1396            synthase for opportunistic infections, *ACS Med. Chem. Lett.*, 4 (2013) 1148–1151.
- 1397    [191] H. Sharma, M.J. Landau, M.A. Vargo, K.A. Spasov, K.S. Anderson, First three-  
1398            dimensional structure of *toxoplasma gondii* thymidylate synthase-dihydrofolate  
1399            reductase: Insights for catalysis, interdomain interactions, and substrate channeling,  
1400            *Biochemistry*, 52 (2013) 7305–7317.
- 1401    [192] R.H. O’Neil, R.H. Lilien, B.R. Donald, R.M. Stroud, A.C. Anderson, Phylogenetic  
1402            Classification of Protozoa Based on the Structure of the Linker Domain in the  
1403            Bifunctional Enzyme, Dihydrofolate Reductase-Thymidylate Synthase, *J. Biol. Chem.*,  
1404            278 (2003) 52980–52987.
- 1405    [193] A.C. Anderson, Two crystal structures of dihydrofolate reductase-thymidylate synthase  
1406            from *Cryptosporidium hominis* reveal protein-ligand interactions including a structural  
1407            basis for observed antifolate resistance, *Acta Crystallogr. Sect. F. Struct. Biol. Cryst.*  
1408            *Commun.*, 61 (2005) 258–62.
- 1409    [194] D.B. Bolstad, E.S.D. Bolstad, K.M. Frey, D.L. Wright, A.C. Anderson, Structure-  
1410            Based Approach to the Development of Potent and Selective Inhibitors of  
1411            Dihydrofolate Reductase from *Cryptosporidium*, *J. Med. Chem.*, (2008) 6839–6852.
- 1412    [195] V.P. Kumar, K.M. Frey, Y. Wang, H.K. Jain, A. Gangjee, K.S. Anderson, Substituted  
1413            pyrrolo[2,3-d]pyrimidines as *Cryptosporidium hominis* thymidylate synthase  
1414            inhibitors, *Bioorganic Med. Chem. Lett.*, 23 (2013) 5426–5428.
- 1415    [196] A. Mukerjee, P. Iyidogan, A. Castellanos-Gonzalez, J.A. Cisneros, D. Czyzyk, A.P.  
1416            Ranjan, W.L. Jorgensen, A.C. White, J.K. Vishwanatha, K.S. Anderson, A nanotherapy  
1417            strategy significantly enhances anticryptosporidial activity of an inhibitor of  
1418            bifunctional thymidylate synthase-dihydrofolate reductase from *Cryptosporidium*,  
1419            *Bioorg. Med. Chem. Lett.*, 25 (2015) 2065–7.
- 1420    [197] W. Sirawaraporn, T. Sathitkul, R. Sirawaraporn, Y. Yuthavong, D. V Santi, Antifolate-  
1421            resistant mutants of *Plasmodium falciparum* dihydrofolate reductase, *Proc. Natl. Acad.*  
1422            *Sci. U. S. A.*, 94 (1997) 1124–1129.
- 1423    [198] S. Kamchonwongpaisan, R. Quarrell, N. Charoensetukul, R. Ponsinet, T. Vilaivan, J.  
1424            Vanichtanankul, B. Tarnchompoo, W. Sirawaraporn, G. Lowe, Y. Yuthavong,

- 1425 Inhibitors of Multiple Mutants of Plasmodium falciparum Dihydrofolate Reductase and  
1426 Their Antimalarial Activities, J. Med. Chem., 47 (2004) 673–680.
- 1427 [199] T. Dasgupta, P. Chitnumsub, C. Maneeruttanarungroj, S. Kamchonwongpaisan, S.E.  
1428 Nichols, T.M. Lyons, J. Tirado-Rives, W.L. Jorgensen, Y. Yuthavong, K.S. Anderson,  
1429 Exploiting Structural Analysis, in Silico Screening, and Serendipity To Identify Novel  
1430 Inhibitors of Drug-Resistant Falciparum Malaria, ACS Chem. Biol., 4 (2009) 29–40.
- 1431 [200] A. Nzila, M. Rottmann, P. Chitnumsub, S.M. Kiara, S. Kamchonwongpaisan, C.  
1432 Maneeruttanarungroj, S. Taweechai, B.K.S. Yeung, A. Goh, S.B. Lakshminarayana, B.  
1433 Zou, J. Wong, N.L. Ma, M. Weaver, T.H. Keller, V. Dartois, S. Wittlin, R. Brun, Y.  
1434 Yuthavong, T.T. Diagana, Preclinical evaluation of the antifolate QN254, 5-chloro-  
1435 n'6'- (2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug  
1436 candidate, Antimicrob. Agents Chemother., 54 (2010) 2603–2610.
- 1437 [201] S. Tirakarn, P. Riangrunroj, P. Kongsaree, M. Imwong, Y. Yuthavong, U.  
1438 Leartsakulpanich, Cloning and heterologous expression of Plasmodium ovale  
1439 dihydrofolate reductase-thymidylate synthase gene, Parasitol. Int., 61 (2012) 324–332.
- 1440 [202] V. Somsak, C. Uthaipibull, P. Prommana, S. Srichairatanakool, Y. Yuthavong, S.  
1441 Kamchonwongpaisan, Transgenic Plasmodium parasites stably expressing Plasmodium  
1442 vivax dihydrofolate reductase-thymidylate synthase as in vitro and in vivo models for  
1443 antifolate screening, Malar. J., 10:291 (2011) 1–10.
- 1444 [203] S. Bunyarataphan, U. Leartsakulpanich, S. Taweechai, B. Tarnchompoo, S.  
1445 Kamchonwongpaisan, Y. Yuthavong, Evaluation of the activities of pyrimethamine  
1446 analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate  
1447 reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial  
1448 complementation assays, Antimicrob. Agents Chemother., 50 (2006) 3631–7.
- 1449 [204] M.A. Vargo, W.E. Martucci, K.S. Anderson, Disruption of the crossover helix impairs  
1450 dihydrofolate reductase activity in the bifunctional enzyme TS-DHFR from  
1451 Cryptosporidium hominis, Biochem. J., 417 (2009) 757–64.
- 1452 [205] C.K.T. Pang, J.H. Hunter, R. Gujjar, R. Podutoori, J. Bowman, D.G. Mudeppa, P.K.  
1453 Rathod, Catalytic and ligand-binding characteristics of Plasmodium falciparum serine  
1454 hydroxymethyltransferase, Mol. Biochem. Parasitol., 168 (2009) 74–83.
- 1455 [206] K. Sopitthummakhun, S. Maenpuen, Y. Yuthavong, U. Leartsakulpanich, P. Chaiyen,  
1456 Serine hydroxymethyltransferase from Plasmodium vivax is different in substrate  
1457 specificity from its homologues, FEBS J., 276 (2009) 4023–4036.
- 1458 [207] S. Maenpuen, K. Sopitthummakhun, Y. Yuthavong, P. Chaiyen, U. Leartsakulpanich,  
1459 Characterization of Plasmodium falciparum serine hydroxymethyltransferase-A  
1460 potential antimalarial target, Mol. Biochem. Parasitol., 168 (2009) 63–73.
- 1461 [208] W. Pornthanakasem, D. Kongkasuriyachai, C. Uthaipibull, Y. Yuthavong, U.  
1462 Leartsakulpanich, Plasmodium serine hydroxymethyltransferase: indispensability and  
1463 display of distinct localization, Malar. J., 11:387 (2012) 1–9.
- 1464 [209] C. Pinthong, S. Maenpuen, W. Amornwatcharapong, Y. Yuthavong, U.  
1465 Leartsakulpanich, P. Chaiyen, Distinct biochemical properties of human serine  
1466 hydroxymethyltransferase compared with the Plasmodium enzyme: implications for

- selective inhibition, FEBS J., 281 (2014) 2570–2583.
- [210] K. Sopitthummakhun, C. Thongpanchang, T. Vilaivan, Y. Yuthavong, P. Chaiyen, U. Leartsakulpanich, Plasmodium serine hydroxymethyltransferase as a potential anti-malarial target: inhibition studies using improved methods for enzyme production and assay, Malar. J., 11:194 (2012) 1–12.
- [211] M.C. Witschel, M. Rottmann, A. Schwab, U. Leartsakulpanich, P. Chitnumsub, M. Seet, S. Tonazzi, F. Stelzer, T. Mietzner, C. Mcnamara, F. Thater, A. Jaruwat, C. Pinthong, P. Riengrunroj, M. Ou, M. Hamburger, P. Ma, L.M. Sanz-alonso, S. Charman, S. Wittlin, et al., Inhibitors of Plasmodial Serine Hydroxymethyltransferase (SHMT): Cocrystal Structures of Pyrazolopyrans with Potent Blood- and Liver- Stage Activities, 58 (2015) 3117–3130.
- [212] S. Chaturvedi, V. Bhakuni, Unusual structural, functional, and stability properties of serine hydroxymethyltransferase from Mycobacterium tuberculosis, J. Biol. Chem., 278 (2003) 40793–805.
- [213] S. Sharma, V. Bhakuni, Cloning and structural analysis of Mycobacterium leprae serine hydroxymethyltransferase, Protein Expr. Purif., 55 (2007) 189–97.
- [214] R. Vatsyayan, U. Roy, Molecular cloning and biochemical characterization of Leishmania donovani serine hydroxymethyltransferase, Protein Expr. Purif., 52 (2007) 433–440.
- [215] S. Gandhi, N. Gaur, S. Krishna, M.I. Siddiqi, J.K. Saxena, Arg-265: A critical residue of L.donovani cytosolic SHMT in maintaining the binding of THF and catalysis, Exp. Parasitol., 149 (2015) 16–23.
- [216] D.G.S. Capelluto, U. Hellman, J.J. Cazzulo, J.J.B. Cannata, Purification and partial characterization of three isoforms of serine hydroxymethyltransferase from Crithidia fasciculata, Mol. Biochem. Parasitol., 98 (1999) 187–201.
- [217] D.G. Capelluto, U. Hellman, J.J. Cazzulo, J.J. Cannata, Purification and some properties of serine hydroxymethyltransferase from Trypanosoma cruzi, Eur. J. Biochem., 267 (2000) 712–719.
- [218] V.N. Dobrovolsky, T. Bucci, R.H. Heflich, J. Desjardins, F.C. Richardson, Mice deficient for cytosolic thymidine kinase gene develop fatal kidney disease, Mol. Genet. Metab., 78 (2003) 1–10.
- [219] M. Thiel, S. Harder, M. Wiese, M. Kroemer, I. Bruchhaus, Involvement of a Leishmania thymidine kinase in flagellum formation, promastigote shape and growth as well as virulence, Mol. Biochem. Parasitol., 158 (2008) 152–62.
- [220] J. Timm, C. Bosch-Navarrete, E. Recio, J.E. Nettleship, H. Rada, D. González-Pacanowska, K.S. Wilson, Structural and Kinetic Characterization of Thymidine Kinase from Leishmania major, PLoS Negl. Trop. Dis., 9 (2015) e0003781.
- [221] F. Ranjbarian, M. Vodnala, S.M. Vodnala, R. Rofougaran, L. Thelander, A. Hofer, Trypanosoma brucei thymidine kinase is tandem protein consisting of two homologous parts, which together enable efficient substrate binding, J. Biol. Chem., 287 (2012) 17628–36.

- 1508 [222] X.E. Sun, L. Sharling, M. Muthalagi, D.G. Mudeppa, K.W. Pankiewicz, K. Felczak,  
1509 P.K. Rathod, J. Mead, B. Striepen, L. Hedstrom, Prodrug activation by  
1510 Cryptosporidium thymidine kinase, *J. Biol. Chem.*, 285 (2010) 15916–15922.
- 1511 [223] Q. Cui, W.S. Shin, Y. Luo, J. Tian, H. Cui, D. Yin, Thymidylate Kinase: An Old Topic  
1512 Brings New Perspectives, *Curr. Med. Chem.*, 20 (2013) 1286 – 1305.
- 1513 [224] G. Martínez-Botella, J.N. Breen, J.E.S. Duffy, J. Dumas, B. Geng, I.K. Gowers, O.M.  
1514 Green, S. Guler, M.F. Hentemann, F.A. Hernandez-Juan, D. Joseph-McCarthy, S.  
1515 Kawatkar, N.A. Larsen, O. Lazari, J.T. Loch, J.A. Macritchie, A.R. McKenzie, J. V.  
1516 Newman, N.B. Olivier, L.G. Otterson, et al., Discovery of selective and potent  
1517 inhibitors of gram-positive bacterial thymidylate kinase (TMK), *J. Med. Chem.*, 55  
1518 (2012) 10010–10021.
- 1519 [225] T.A. Keating, J. V. Newman, N.B. Olivier, L.G. Otterson, B. Andrews, P.A. Boriack-  
1520 Sjodin, J.N. Breen, P. Doig, J. Dumas, E. Gangl, O.M. Green, S.Y. Guler, M.F.  
1521 Hentemann, D. Joseph-Mccarthy, S. Kawatkar, A. Kutschke, J.T. Loch, A.R.  
1522 McKenzie, S. Pradeepan, S. Prasad, et al., In vivo validation of thymidylate kinase  
1523 (TMK) with a rationally designed, selective antibacterial compound, *ACS Chem. Biol.*,  
1524 7 (2012) 1866–1872.
- 1525 [226] J.Y. Choi, M.S. Plummer, J. Starr, C.R. Desbonnet, H. Soutter, J. Chang, J.R. Miller,  
1526 K. Dillman, A.A. Miller, W.R. Roush, Structure guided development of novel  
1527 thymidine mimetics targeting *Pseudomonas aeruginosa* thymidylate kinase: From hit to  
1528 lead generation, *J. Med. Chem.*, 55 (2012) 852–870.
- 1529 [227] V. Vanheusden, H. Munier-Lehmann, M. Froeyen, L. Dugué, A. Heyerick, D. De  
1530 Keukeleire, S. Pochet, R. Busson, P. Herdewijn, S. Van Calenbergh, 3-C-branched-  
1531 chain-substituted nucleosides and nucleotides as potent inhibitors of *Mycobacterium*  
1532 tuberculosis thymidine monophosphate kinase, *J. Med. Chem.*, 46 (2003) 3811–3821.
- 1533 [228] K.S. Toti, F. Verbeke, M.D.P. Risseeuw, V. Freceer, H. Munier-Lehmann, S. Van  
1534 Calenbergh, Synthesis and evaluation of 5'-modified thymidines and 5-hydroxymethyl-  
1535 2'-deoxyuridines as *Mycobacterium tuberculosis* thymidylate kinase inhibitors,  
1536 *Bioorganic Med. Chem.*, 21 (2013) 257–268.
- 1537 [229] C. Gasse, D. Douguet, V. Huteau, G. Marchal, H. Munier-Lehmann, S. Pochet,  
1538 Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of  
1539 *Mycobacterium tuberculosis*: Synthesis and in vitro anti-mycobacterial activity,  
1540 *Bioorganic Med. Chem.*, 16 (2008) 6075–6085.
- 1541 [230] O. Familiar, H. Munier-Lehmann, J.A. Aínsa, M.J. Camarasa, M.J. Pérez-Pérez,  
1542 Design, synthesis and inhibitory activity against *Mycobacterium tuberculosis*  
1543 thymidine monophosphate kinase of acyclic nucleoside analogues with a distal  
1544 imidazoquinolinone, *Eur. J. Med. Chem.*, 45 (2010) 5910–5918.
- 1545 [231] S. Van Poecke, H. Munier-Lehmann, O. Helynck, M. Froeyen, S. Van Calenbergh,  
1546 Synthesis and inhibitory activity of thymidine analogues targeting *Mycobacterium*  
1547 tuberculosis thymidine monophosphate kinase, *Bioorganic Med. Chem.*, 19 (2011)  
1548 7603–7611.
- 1549 [232] M. Naik, A. Raichurkar, B.S. Bandodkar, B. V. Varun, S. Bhat, R. Kalkhambkar, K.  
1550 Murugan, R. Menon, J. Bhat, B. Paul, H. Iyer, S. Hussein, J.A. Tucker, M. Vogtherr,



- 1551 K.J. Embrey, H. McMiken, S. Prasad, A. Gill, B.G. Ugarkar, J. Venkatraman, et al.,  
1552 Structure Guided Lead Generation for M tuberculosis Thymidylate Kinase (Mtb  
1553 TMK): Discovery of 3-Cyanopyridone and 1,6-Naphthyridin-2-one as Potent  
1554 Inhibitors, *J. Med. Chem.*, 58 (2015) 753–766.
- 1555 [233] H. Cui, J. Carrero-Lérida, A.P.G. Silva, J.L. Whittingham, J.A. Brannigan, L.M. Ruiz-  
1556 Pérez, K.D. Read, K.S. Wilson, D. González-Pacanowska, I.H. Gilbert, Synthesis and  
1557 evaluation of  $\alpha$ -thymidine analogues as novel antimalarials, *J. Med. Chem.*, 55 (2012)  
1558 10948–10957.
- 1559 [234] C. Carnrot, L. Wang, D. Topalis, S. Eriksson, Mechanisms of substrate selectivity for  
1560 *Bacillus anthracis* thymidylate kinase, *Protein Sci.*, 17 (2008) 1486–1493.
- 1561 [235] M.A. Tormo-Más, I. Mir, A. Shrestha, S.M. Tallent, S. Campoy, I. Lasa, J. Barbé, R.P.  
1562 Novick, G.E. Christie, J.R. Penadés, Moonlighting bacteriophage proteins derepress  
1563 staphylococcal pathogenicity islands, *Nature*, 465 (2010) 779–782.
- 1564 [236] J.E. Szabó, V. Németh, V. Papp-Kádár, K. Nyíri, I. Leveles, A.Á. Bendes, I. Zagyva,  
1565 G. Róna, H.L. Pálincás, B. Besztercei, O. Ozohanics, K. Vékey, K. Liliom, J. Tóth,  
1566 B.G. Vértessy, Highly potent dUTPase inhibition by a bacterial repressor protein  
1567 reveals a novel mechanism for gene expression control, *Nucleic Acids Res.*, 42 (2014)  
1568 11912–20.
- 1569 [237] K. Nyíri, B. Köhegyi, A. Micsonai, J. Kardos, B.G. Vértessy, Evidence-Based  
1570 Structural Model of the Staphylococcal Repressor Protein: Separation of Functions into  
1571 Different Domains, *PLoS One*, 10 (2015) e0139086.
- 1572 [238] K. Nyíri, V. Papp-Kádár, J.E. Szabó, V. Németh, B.G. Vértessy, Exploring the role of  
1573 the phage-specific insert of bacteriophage  $\Phi$ 11 dUTPase, *Struct. Chem.*, 26 (2015)  
1574 1425–1432.
- 1575 [239] R. Hirmondó, J.E. Szabó, K. Nyíri, S. Tarjányi, P. Dobrotka, J. Tóth, B.G. Vértessy,  
1576 Cross-species inhibition of dUTPase via the Staphylococcal Stl protein perturbs dNTP  
1577 pool and colony formation in *Mycobacterium*, *DNA Repair (Amst.)*, 30 (2015) 21–7.
- 1578 [240] H.C. Wang, K.C. Hsu, J.M. Yang, M.L. Wu, T.P. Ko, S.R. Lin, A.H.J. Wang,  
1579 *Staphylococcus aureus* protein SAUGI acts as a uracil-DNA glycosylase inhibitor,  
1580 *Nucleic Acids Res.*, 42 (2014) 1354–1364.
- 1581 [241] H.-C. Wang, C.-H. Ho, C.-C. Chou, T.-P. Ko, M.-F. Huang, K.-C. Hsu, A.H.-J. Wang,  
1582 Using structural-based protein engineering to modulate the differential inhibition  
1583 effects of SAUGI on human and HSV uracil DNA glycosylase, *Nucleic Acids Res.*,  
1584 (2016) gkw185.

1585